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ABSTRACT 
The purpose of this work was to investigate the interaction of the pro-inflammatory cytokine, 
IFN-y, and the anti-inflammatory cytokines, TGF-|3 and IL-10, in the subclinical and clinical 
stages of Johne's disease. A retrospective quantitative analysis of IFN-y, IL-10 and TGF-J3 
mRNA gene expression in tissues such as ileum, ileal-cecal junction, ileal-cecal node, and 
mesenteric lymph node obtained from cows naturally infected with Mycobacterium 
paratuberculosis and healthy non-infected control cows revealed an upregulation of IL-10 
and TGF-(3 in tissues obtained from clinically infected animals but not in tissues obtained 
from healthy or subclinically infected cows. Analysis of IFN-y mRNA gene expression in 
these tissues showed that expression of this cytokine is upregulated only in subclinical cows. 
We further evaluated the effects of exogenous IFN-y, IL-10 and TGF-(3 in an extended 
culture system (7-12 days) using unfractionated PBMC cultures from naturally infected and 
healthy non-infected cows after infection with live M. paratuberculosis. We determined that 
the presence of IL-10 and TGF-J3 in culture supernatants was correlated with decreased 
ability of monocyte-derived macrophages in the unfractionated cell cultures to kill M. 
paratuberculosis in vitro, with a resultant decrease in IFN-y production in these cultures. EL-
10 and TGF-(3 were upregulated in response to in vitro infection in cell cultures from infected 
animals regardless of their disease status. Prior to in vitro infection with M. paratuberculosis 
TGF-(3 levels were lower in subclinically infected animals compared to clinically infected or 
healthy animals. After in vitro infection, TGF-(3 levels in culture supernatants of subclinically 
infected animals were similar to that of healthy animals. This is the first study to investigate 
the interactive roles of IFN-y, IL-10 and TGF-(3 in natural and experimental M. 
paratuberculosis infections. The data presented here suggest an important regulatory role of 
anti-inflammatory cytokines IL-10 and TGF-(3 on IFN-y production and the ability of 
macrophages to kill M. paratuberculosis in vitro. 
1 
INTRODUCTION 
The immune system does not always succeed in recognizing and destroying all of the 
organisms that are present in any given infection. Normally the function of the macrophages 
is to ingest and destroy bacteria. When mycobacteria infect the body, they can evade the 
defenses of the host immune system by hiding inside macrophages (2, 7, 10, 11). In early 
stages of mycobacterial infection, the cell-mediated immunity is activated and successful in 
containing but not eliminating the infection (22). This is represented by the increased 
presence of pro-inflammatory cytokines in the contained stage of the disease. When 
mycobacterial infection progresses into clinical stage of the disease, the ability to mount an 
effective cell-mediated immunity appears suppressed as indicated by the decreased 
production and detection of pro-inflammatory cytokines such as IFN-y (22). The reason(s) 
for suppression of the cell-mediated immune response is not completely understood. 
However, the increased presence of anti-inflammatory cytokines such as IL-10 and TGF-(3 as 
the infection progresses to a more clinical stage suggests that it might be an active process 
orchestrated by these cytokines (1, 8, 14, 18, 25, 26). 
There is a great body of evidence that increased expression of IL-10 and TGF-(3 and 
decreased expression of IFN-y may be involved in the transition of mycobacterial infections 
such as tuberculosis or leprosy from contained states to more clinical states. For instance, the 
involvement of IFN-y in tuberculosis is well studied and evidence suggests that this cytokine 
is the most important pro-inflammatory cytokine in defense against M. tuberculosis (3, 5, 6. 
17). Addition of recombinant IFN-y to macrophage cell cultures enhanced the ability of these 
cells to limit M. tuberculosis and M. bovis growth (6, 17). Conversely, infection of IFN-y 
knockout mice with a sublethal dose of M. bovis or M. tuberculosis lead to an increase in 
mortality and increased bacterial recovery from spleen, liver and lung (3, 5). In addition, 
measurement of IFN-y production in response to in vitro mycobacterial antigen stimulation is 
used as an indicator of M. tuberculosis infection (23). Similar to tuberculosis, cytokine 
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involvement in leprosy indicates that the contained and localized infection which is known as 
the tuberculoid form of disease is mediated by a Th-1 type of response represented by IFN-y 
production (1, 15, 25). 
The presence of the anti-inflammatory cytokines that counteract, inhibit and manipulate the 
effects of pro-inflammatory cytokines might be one mechanism for intracellular survival of 
mycobacteria. Evidence obtained from studies with IL-10 transgenic mice and IL-10 
knockout mice indicates that IL-10 is often associated with immune suppression in 
mycobacterial infection and with the enhanced replication of mycobacteria (13). Similarly, 
TGF-(3 has also been shown experimentally to enhance the intracellular growth of M. 
tuberculosis in human monocytes (9). The interaction between IL-10 and TGF-(3 in M. 
tuberculosis infection appears to be synergistic and effective in downregulation of M. 
tuberculosis induced T cell production of IFN-y (16). These two cytokines also were found to 
be upregulated in advanced stage of leprosy (i.e., lepromatous leprosy) (1, 8, 14, 18, 25, 26). 
Similar to other mycobacterial infections, M. paratuberculosis taken up by macrophages can 
evade the aggressive host immune reaction generated inside these cells. This bacterium 
causes chronic enteric disease characterized by intermittent diarrhea, weight loss and 
eventually animal death. The disease progresses from a contained stage that is referred to as a 
subclinical infection where animals are asymptomatic and shed few or no bacteria in their 
feces to a more advanced clinical stage. With progression to the clinical stage of disease, the 
bacterial shedding increases and clinical signs begin to appear. The transition of the disease 
from the subclinical stage to the clinical stage reflects an ongoing host immune response 
struggle. 
Cytokine expression in the two stages of disease is typified by the presence of high levels of 
IFN-y in the contained stage of disease, representing an activation of the host's cell-mediated 
immune response, and a decreased expression and production of this cytokine in the 
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advanced clinical stage. Animals in the excretory subclinical stage are reported to have high 
IFN-y locally at the site of infection in tissues such as ileum and mesenteric lymph nodes 
(21) and produce high amounts of IFN-y in peripheral blood mononuclear cell (PBMC) 
cultures stimulated with M. paratuberculosis antigens (19, 20). This response is 
downregulated when animals progress to the clinical stage of the disease where other 
proinflammatory cytokines such as IL-1(3 and IL-6 become elevated (12, 20). This suggests 
that an immunomodulatory response alters an effective cell-mediated immunity represented 
by the presence of IFN-y in the subclinical animals. Recently, two reports correlated the 
presence of IL-10 with the clinical stage of M. paratuberculosis infection. The first study 
reported that stimulation of PBMC obtained from two clinically infected cows with ConA 
upregulated the gene expression of IL-10 more than cells obtained from healthy and 
subclinically infected cows (4). Another reported that after stimulation of monocyte-derived 
macrophage cultures obtained from two non-infected cows with live M. paratuberculosis, IL-
10 gene expression was significantly elevated at all time points (i.e., 6h, 24h and 72h) 
compared to non-stimulated cell culture (24). In regards to TGF-(3, no report addresses the 
role of this important immunoregulatory cytokine in bovine M. paratuberculosis infection. 
In this study, we investigated the involvement of IL-10 and TGF-(3 in Johne's disease. 
Similar to other mycobacterial infections, IL-10 and TGF-(3 were found to negatively control 
M. paratuberculosis infection. We found that exogenous addition of these two anti­
inflammatory cytokines downregulated the ability of monocyte-derived macrophages in the 
extended (7-12 days) unfractionated PBMC culture to kill live M. paratuberculosis in vitro. 
Moreover, these cytokines resulted in a reduction in IFN-y production in all groups (i.e., 
healthy and naturally infected groups) with more pronounced inhibitory effects noted in cell 
cultures from subclinically infected animals. We also found that these two cytokines were 
specifically induced in PBMC cultures obtained only from infected animals regardless of 
their disease status after stimulation with live M. paratuberculosis. However, before 
stimulation with live M. paratuberculosis, PBMC from subclinically infected animals 
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produced less TGF-(3 when incubated in control medium than cells from clinically infected 
and healthy animals. After in vitro infection, TGF-(3 production increased in cell cultures of 
subclinically infected animals and became similar to the levels of production in cell cultures 
of healthy animals. This study also determined that these anti-inflammatory cytokines were 
expressed at higher levels in tissues from clinically infected cows compared to tissues from 
subclinically infected or healthy cows. In contrast, the gene expression of the pro­
inflammatory cytokine, IFN-y, was higher in tissues from subclinically infected animals 
compared to healthy or clinically infected animal tissues. 
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CHAPTER ONE: LITERATURE REVIEW 
Introduction to Johne's Disease 
Johne's disease is a chronic enteric disease characterized by intermittent diarrhea, weight loss 
and death. The causative agent of Johne's disease is Mycobacterium paratuberculosis. This 
organism has been shown to infect a wide variety of animals including cattle, sheep, goats, 
camels, bison, and deer (100, 151). Typically, cattle first encounter the infection during the 
first twelve months of life (93). It is likely that the infection occurs through the ingestion of 
milk, feed or water that has been contaminated by manure containing M. paratuberculosis 
(27, 157, 160). Up to ten percent of calves are infected with M. paratuberculosis through 
vertical transmission from the dam to the fetus (161). The primary site of infection for M. 
paratuberculosis is the intestine; thus, fecal material is the most common vehicle for disease 
transmission and ingestion of contaminated fecal material is considered the common means 
for M. paratuberculosis infection. Milk from infected dams is another source of M. 
paratuberculosis infection (157, 160). The duration that the calves spend with infected dams 
as well as the frequency of nursing increases the probability for young animals to become 
infected (157). In addition to ingestion of the bacteria that are excreted into the mother's 
milk, calves may also become infected through fecal contamination present on the teats 
(157). 
The excretion of M. paratuberculosis in the milk of infected cows increases as the infection 
progresses (160). At early stages of the disease when fecal shedding was light only 3% of 
milk samples and 6% of supramammary lymph node samples were positive for M. 
paratuberculosis (160). When the disease state and M. paratuberculosis shedding in feces 
was intermediate, the percentage of milk samples that were positive for M. paratuberculosis 
increased to 11% of (i.e., one sample out of 9 tested milk samples) and 22% of 
supramammary lymph node samples (i.e., two samples out of 9 tested samples) (160). In 
animals that were heavy shedders, the percentage of milk and supramammary lymph node 
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samples that were positive for M. paratuberculosis increased to 19% (i.e., 7 samples out of 
37 tested samples) and 46% (i.e., 18 samples out of 39 tested samples), respectively (160). 
Therefore, the risk of calf infection increased if they were fed milk of heavily infected dams. 
Johne's disease typically progresses through three distinct stages (Table 1) (27). The division 
of these stages depends upon the existence of clinical signs and the correlation of these signs 
with fecal bacterial shedding. Accordingly, the first and the second stages are considered 
subclinical stages where animals are asymptomatic. Animals may remain in these stages 
without developing clinical disease or might progress into showing clinical signs after 3-4 
years of infection. During the first subclinical stage, the infectious process develops without 
detectable fecal shedding followed by the subclinical intermittent excretory phase (stage II). 
The third or the clinical excretory stage is characterized by progressive symptoms associated 
with chronic shedding of high levels of bacteria in the feces and severe diarrhea with 
concomitant weight loss. 
Table 1. Stages of Johne's disease. 
Stage Fecal shedding Clinical signs Animal Age 
Stage I light None Calves, heifers and adults 
Stage II Intermediate None Adults (3-4 years) 
Stage III Heavy Present Adults older than 4 years 
Johne's disease in the adult cows is characterized by persistent diarrhea, emaciation, normal 
or increased appetite, absence of fecal blood or mucus and non-responsiveness to standard 
antibiotic treatment (188). Other clinical manifestations that occur in advanced cases, 
sometimes referred to as stage IV, include lethargy, weakness and submandibular edema 
(188). Submandibular edema, also known as bottle jaw, is a typical clinical sign of an 
advanced Johne's disease. It occurs as a result of decreased intestinal function with loss of 
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albumin (i.e., protein-losing enteropathy), and edema formation secondary to 
hypoproteinemia. Dependence upon these clinical signs alone for diagnostic purposes will 
not deterimne the extent of M. paratuberculosis infection in the herd. Due to the difficulties 
in detecting animals within the long incubation period (i.e., stage I and II), there is a great 
underestimation of the numbers of infected animals identified within any given herd. 
However, diagnosis of a single clinical case may be an indication of a serious herd problem 
and represent the " tip of the iceberg" on that farm (188). 
There are many available tests to detect animals with Johne's disease. These tests include 
detection of the bacterium by culture or PGR, or detection of either humoral or cell-mediated 
immune response (CMI). The most sensitive and accurate method for Johne's disease 
diagnosis is to detect the bacterium that causes the infection. There are three ways to detect 
infection through identification of the microorganism. Two of these methods focus on 
isolation of the entire organism: standard culture and BACTEC radiometric culture. Standard 
c o n v e n t i o n a l  c u l t u r e  m e t h o d s  u s i n g  H e r r o l d ' s  e g g  b a s e d  m e d i u m  ( H E Y M )  m a y  t a k e  2 - 3  
months before a colony is visible on the surface of the medium (28). BACTEC culture 
methods take advantage of the speed and sensitivity of the radioisotope-based detection and 
growth of M. paratuberculosis can easily be noted within 2 -4 weeks (28, 92). It basically 
correlates the amount of C02 release in the vial containing M. paratuberculosis to a 
statistically calculated growth index (92). Compared to the standard culture methods which 
could detect as low as 15 -50 organisms per gram of feces (28, 131, 139), the BACTEC 
culture method is more sensitive and permits the detection of as few as 3 organisms per gram 
of feces (28). The BACTEC culture method is also less likely to be influenced by bacterial 
clumping (28). Moreover, the contamination rate reported in the BACTEC radiometric 
culture is as low as 3.95% when the concentration of the fecal specimen is applied by 
filtration (28). This is half the contamination rate reported with conventional standard culture 
on HEYM (28). However, M. paratuberculosis growth confirmation is required with 
BACTEC by Ziehl-Neelsen stain, since the colonies cannot be visually identified as they are 
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on HEYM and often contaminating microorganisms may cause false positive readings. 
Unfortunately, most infected animals are asymptomatic and either do not continuously shed 
M. paratuberculosis or shed the bacterium in undetectable numbers. Even when the number 
and the frequency of M. paratuberculosis shedding increases in clinical stage, it is still 
impractical to use bacterial isolation as a diagnostic tool due to the slow growing nature of 
M. paratuberculosis. 
The third diagnostic method that depends upon bacterial detection is fast, but is relatively 
less sensitive than culture methods. This test depends on the detection of M. paratuberculosis 
specific genes through PGR. The major limitation with this detection method is to find the 
gene or genes that are specific to M. paratuberculosis and are not shared with M. avium or 
other closely related environmental mycobacteria. The most routinely utilized gene sequence 
to detect M. paratuberculosis infection is IS900. This insertion sequence is present in 
multiple copies with approximately 10 -20 genomic copies in all tested M. paratuberculosis 
strains but absent in most M. avium genomic DNA (177). Sequences related to IS900 have 
recently been isolated from some M. avium and other mycobacterial strains. For example, 
clinical strains of M. avium isolated from HIV patients were positive for IS900 (115). 
Moreover, recent studies reported the presence of sequences that have 71 - 79% homology to 
M. paratuberculosis IS900 in M. scrofulaceum and M. marinum (85). A single IS900 copy 
was also found in M. cookii that carries up to 94% homology to M. paratuberculosis IS900 
(47). 
Despite the limitation of IS900 specificity, several studies reported an improvement in both 
sensitivity and specificity using IS900 PGR for M. paratuberculosis detection. For example, 
the use of real time PGR to detect M. paratuberculosis IS900 not only quantitated M. 
paratuberculosis but also obtained results highly comparable in its sensitivity to fecal culture 
results (50). When the real time PGR method for IS900 was tested for its specificity and 
compared with fecal culture of 41 specimens, only one sample tested positive with the real­
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time PGR and not with fecal culture. This suggests either a low number of bacteria that were 
not viable and therefore couldn't be detected by culture but could be detected by PGR; or that 
the real time PGR was detecting IS900 from a closely related environmental mycobacterium. 
Consequently, the need to find more specific genes to confirm the presence of M. 
paratuberculosis is still a necessity. Recently, twenty-seven new coding sequences from M. 
paratuberculosis have been identified via total genome sequencing, compared with M. avium 
and were shown to be specific for M. paratuberculosis (8). These sequences might be further 
used to improve the sensitivity and specificity of PGR as a molecular diagnostic tool. 
In ruminants, M. paratuberculosis infection leads to the development of both cellular and 
humoral immunity. During the subclinical stage of Johne's disease, IFN-y secretion by 
peripheral blood mononuclear cells (PBMC) is elevated in response to M. paratuberculosis 
infection (148, 158). Therefore, an IFN-y ELIS A has been developed to aid in the detection 
of animals at this critical stage of the disease. Later, after animals progress to the clinical 
stage, the cell-mediated immunity begins to decrease and humoral immunity increases. 
Animals in the clinical stage have elevated serum antibodies that are specific to infection 
with M. paratuberculosis (27). This humoral immune response is not helpful in protecting 
animals but has a great benefit in confirming the presence of M. paratuberculosis infection. 
The antibody response becomes stronger as animals progress further in the clinical stage of 
the disease and shed large numbers of bacteria in their feces, while animals in the subclinical 
stage of disease have negligible antibody levels. For example, only 15% of cows identified as 
low M. paratuberculosis shedders (i.e., subclinical Johne's cows) tested positive for M. 
paratuberculosis-specific antibodies by ELIS A versus 87% detected positive among the high 
shedders (i.e., clinical cows) (36, 159). Therefore, using antibody detection as a diagnostic 
tool is limited primarily to animals that are in the clinical stage of disease and cannot be 
employed to identify infected animals in the subclinical stage of the disease. In other words, 
when testing herds for Johne's disease, tests for IFN-y and antibody response should be done 
in parallel in order to detect the animals that are in the subclinical stage and in the clinical 
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stage, respectively. For instance among 16 cows that were identified as low shedders, the 
IFN-y assay detected 8 cows as positive producers of IFN-y while M. paratuberculosis-
specific antibody ELIS A detected another 4 cows (36). In animals with clinical stage of the 
disease and high bacterial shedding, 2 out of 6 cows tested were positively detected by IFN-y 
assay and the others were positive based upon the presence of antibody (36). 
Other tests used to evaluate CMI are based on measurements of lymphocyte proliferation or 
migration. Peripheral blood mononuclear cells (PBMC) were obtained from M. 
paratuberculosis-infected. animals and stimulated with concanavalin A (Con A) or with 
either M. paratuberculosis or M. bovis purified protein derivatives (88). PBMC cultures from 
the infected animals that were stimulated with Con A had lower proliferation capacity than 
cell cultures obtained from non-infected animals, while stimulation with PPD induced higher 
proliferative responses in the infected animals. In addition, placing peripheral blood 
mononuclear cells in agar plates then stimulating them with johnin resulted in an inhibition in 
the ability of cells obtained from infected animals to migrate in agar (10). However, neither 
assay has been adopted as a tool of routine diagnosis of Johne's disease cases. Both assays 
involve the isolation of leukocytes from peripheral blood and require long incubation periods 
(3-7 days) (88). In addition, IFN-y measurement correlates well with the results of 
lymphocyte proliferation and migration assays, requires a shorter incubation period and is 
less labor intensive. Therefore, the IFN-y assay is more preferable than lymphocyte 
proliferation and migration assays. 
The long incubation period, difficulty in early detection, lack of an effective vaccine and the 
poor understanding of the pathogenesis of this disease makes it very difficult to develop an 
effective control program and thus exacerbates the economic impact of this disease. Control 
programs mainly suggest culling the animals that show clinical signs (135). Although this 
might lead to the eradication of infected animals from the herd in the long run, it has a great 
economic impact on the herd productivity. It also increases the overall cull rate and reduces 
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the culling of other less productive animals because it forces the owner to cull valuable 
animals with great productivity or outstanding desirable genetics because they become 
infected or were exposed to M. paratuberculosis (77). Other economic losses are mainly due 
to the decreased weight and decreased milk production, which may reach as high as 25% 
over lactation in infected animals (77). 
In addition to the direct economic impact of Johne's disease on the animal industry, some 
evidence suggests that M. paratuberculosis is a potential agent in a chronic enteric disease in 
humans, known as Crohn's disease (CD). This disorder shares some clinical symptoms with 
Johne's disease. Both are chronic granulomatous diseases affecting gut nutrient absorption 
and fluid retention, leading to diarrhea and continuous weight loss (163). Although the 
causative agent has not been specified in CD, some studies have isolated M. paratuberculosis 
from tissues of infected individuals. Isolation of M. paratuberculosis from some CD patients 
was first reported in 1984 (163). Recently, using improved culture techniques and IS900 
PCR on centrifugal pellets obtained from surgically resected guts from Crohn's disease 
patients, 20% of the biopsies were positives for M. paratuberculosis (142). Another study 
showed detection of M. paratuberculosis in 72% of intestinal biopsy samples from CD by 
employing an in situ hybridization method using the IS900 probe (76). The same study 
concluded that infection might be caused by cell wall-deficient M. paratuberculosis since no 
bacteria were detected by Ziehl-Neelsen staining. Another study also correlated M. 
paratuberculosis with CD by demonstrating the presence of M. paratuberculosis in the 
centrifugal pellets of breast milk from 2 mothers with Crohn's disease (116). However, there 
is still a strong debate concerning the causative agent of CD as other bacterial and viral 
pathogens have been implicated in this disorder (132, 175). Nevertheless, the possible 
association of M. paratuberculosis with CD is another reason to develop mandatory 
programs to control Johne's disease. 
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The key element to control Johne's disease is mainly achieved through herd management. 
Testing animals provides information about the presence, extent of infection and the number 
of infected animals in the herd. Once the extent of the infection is identified, appropriate 
management must follow to prevent bacterial exposure of susceptible newborn calves (135). 
The main control element is to prevent oral manure contamination by infected adults to 
calves (135). The control strategies to achieve this goal vary according to each farm situation. 
Housing young calves in separate facilities from adult cattle and then following strict 
sanitation procedures to ensure this separation is a key in any successful control program 
(135). It is also helpful to feed calves milk obtained only from Johne's negative cows, use 
milk replacer or pasteurize the dam's milk prior to consumption (135). Another important 
point is to reduce the total farm exposure level to M. paratuberculosis by removing the 
bacteria from the environment and reducing the number of infected animals that are shedding 
the bacteria, with the most severely infected cows to be culled first (135). In the end it is 
important to be aware that complete eradication of Johne's disease from an infected herd is 
likely to take many years and also needs to be applied in a mandatory rather than through 
voluntary control programs. 
Immunology of the Gastrointestinal Tract in Health and Disease 
The mucosal immune system at the gastrointestinal tract is functionally divided into 
inductive and effector sites (101). An inductive site is where the antigen uptake and 
processing occurs. The main inductive site in the gastrointestinal tract is the Peyer's patches 
in the ileum (101). Peyer's patches are large aggregates of lymphoid tissue which lie beneath 
the interior surface of the intestine. The aggregates are organized clusters of antigen 
presenting cells (APC), mainly macrophages and dendritic cells, overlying B cell follicles 
and interfollicular regions enriched in T lymphocytes (82, 101). This lymphoid dome is 
covered with specialized epithelial cells called M cells (82). These cells translocate antigens 
found in the intestinal lumen to the Peyer's patches where they are ingested by the APCs, 
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then processed and presented to the lymphocytes. This antigen exposure at the inductive site 
is very important for the education of the immune system to its surrounding environment. 
Presentation of the antigen to CD4+ T cells leads to their differentiation into functionally 
distinct subsets of cells. The type of cells generated controls the balance between antigen 
responsiveness and antigen unresponsiveness (118). CD4+ T cells at these inductive sites can 
differentiate into T helper 1 (Th-1) cells that secrete cytokines such as IFN-y and TNF-a; T 
helper 2 (Th-2) cells that secrete IL-4, IL-5, IL-9, IL-10 and IL-13; T helper 3 (Th-3 cells) 
that mainly produce IL-10 and TGF-(3, or regulatory T cells (Tr cells) that mainly produce 
IL-10 (66, 133, 184, 185). Once these cells differentiate into effector T cells they migrate out 
to the regional lymph nodes then into the peripheral blood and later home to mucosal tissues 
(i.e., effector sites) (81, 82, 101). These T cells and their associated pro-inflammatory or anti­
inflammatory cytokines play an important role in maintaining healthy and protective mucosal 
surfaces (152, 153). 
Due to the abundant antigen load, exposure of the lymphoid aggregates in the Peyer's patches 
to most antigens results in a state of immunological unresponsiveness (152). However, 
selected antigens can provoke an immune response that will result in effective cell-mediated 
and/or antibody-mediated immune responses (15, 133). The site of entrance and the dose of 
the antigen, the manner in which the antigen is presented to APCs and the cytokines present 
at the time of T cell - APC interaction determine the outcome of T cell activation and 
differentiation (82, 133, 152). For instance, a very low continuous doses of antigen or a very 
high single dose of antigen leads to a state of tolerance to that particular antigen (Th-3 or Tr 
cells development). A low level of antigen presentation on the surface of APCs causes 
activation of T cells and differentiation that bias toward Th-2 cells while a high level of 
antigens presentation at the surface of APCs causes differentiation to Th-1 cells. 
Alternatively, a high dose of antigen processed and presented by enterocytes expressing 
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MHC II can lead to a state of tolerance. This is mainly due to the inability of these cells to 
provide the appropriate co-stimulatory signal required for generating strong T cell activation. 
T helper cell differentiation is also affected by the presence of cytokines and chemokines. 
Cytokines such as IL-12 and IL-18, for example, direct cell differentiation towards Th-1 cells 
(9), whereas IL-4 and IL-13 induce Th-2 differentiation (106, 123). TGF-(3 and IL-10 are 
involved in a positive feed back mechanism that results in the up-regulation of Th-3 and Tr 
cell activation (66, 143). Chemokines such as I-TAC (IFN-inducible T cell alpha-
chemoattractant), Mig (monokine induced by IFN-y), and IP10 (IFN-inducible protein 10) 
are expressed on Th-1 cells and favor Th-1 recruitment and down regulate Th-2 recruitment 
though emphasize Th-1 polarization (97). 
Other factors involved in the commitment of T cell differentiation include co-stimulatory 
factors and transcriptional factors present at the time of T cell differentiation as well as the 
type of antigen presenting cells. For example the co-stimulatory molecules such as 0X40 on 
APCs and OX4QL on T cells prime T cells towards Th-2 development (56, 123). The 
inducible costimulator (ICOS) expression on APCs and ICOSL on T cells leads to the 
production of IL-10 which mainly induces Th-2 development (105, 190). Alternatively, 
CD40/CD40L interaction primes T cells bearing CD40L towards Th-1 development (17, 
124). The interaction of CD4+ T cells with immature DC seems to preferentially induce Tr, 
CD8a DC interaction with CD4+ T cells induces Th-2 differentiation, while interactions with 
CD8a+ DC produce cytokines such as IL-12 that lead to Th-1 differentiation (49, 90, 102). 
Finally, the activation of transcription factors such as T-bet and STAT-4 direct T cells 
differentiation toward Th-1 cells (110) while GATA-3, c-maf and NFATcl have been shown 
to induce IL-4 production by T cells and, therefore, favor Th-2 development (84, 195, 199). 
Differentiation of T cells depends upon the combination of the factors mentioned above. The 
resultant population of T cells generated controls the balance between activation of a 
protective immune response and the development of tolerance. 
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On the other hand, disturbance of Th-1 and Th-2 homeostatic balance at the mucosal surfaces 
of the gastrointestinal tract may lead to the development of immunological disorder. The 
uncontrolled action of both Th-1 and Th-2 cells contribute to the induction of intestinal 
inflammation. However, the uncontrolled action of these cells may be regulated by cytokines 
produced from Tr and Th-3 cells (14). Intrarectal administration of oxazolone to SJL/J mice 
(i.e., a Th-2 mediated colitis model) caused a rapid onset (i.e., 2 days) of colitis marked by 
weight loss and diarrhea and leading to death of 50% of the mice by day 4 (14). When T cells 
extracted from the inflamed lamina propria were cultured in vitro without stimulation, they 
produced 10-fold higher IL-4 production and 15-fold higher TGF (3 production than cells 
isolated from non-inflamed lamina propria mononuclear cell culture (LPMC) (14). Mice 
administered anti-IL-4 antibody quickly regained the lost weight and were near baseline 
weight within 4 days of oxazolone/ antibody administration (14). In contrast, mice 
administered anti-TGF-(3 antibody developed a severe colitis that involved the entire length 
of the colon and was associated with severe weight loss (14). The immune response 
manifestation and the histopathological changes observed in this experiment were similar to 
that reported in ulcerative colitis patients (14). 
Colitis induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) administration is Th-1-
mediated (87) colitis and similar to the oxazolone colitis model (Th-2-mediated colitis) TGF-
(3 is responsible for the decrease in disease and lesion mainfestaion (119). Mice fed 
haptenized colonic proteins (HCP) before rectal administration of TNBS generated mucosal 
T cells producing high TGF-p (Th-3 cells) and Th-2 like cytokines (Tr cells) that caused 
abrogation of Th-1 cytokines such as IFN-y and IL-12 and consequently led to suppression of 
TNBS induced colitis (87). Similarly, colitis induced by TNBS was prevented by 
administration of TGF-(3 plasmid intranasally to mice (87). This administration of TGF-(3l 
caused an increase in serum TGF-(3 and an increase in the presence of TGF-(3 DNA detected 
by PGR in intestinal mucosal tissues. In addition, stimulation of LPMCs isolated from mice 
given TNBS via the rectum and intranasally administered TGF-(3 plasmid produced 
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decreased levels of IFN-y and IL-1, high amounts of TGF-(3 and a striking increase in IL-10 
production compared to mice not administered TGF-(3 plasmid (87). 
Involvement of Th-1 cells in mucosal inflammation in Crohn's disease (CD) is well 
established (58, 127). Aberrant mucosal Th-1 cell activation and production of IL-12, the 
major Th-1 driving factor was found to be associated with Crohn's disease (11, 127). CD4+ 
cells isolated from the lamina propria of CD patients display a Th-1 cytokine pattern where 
they are able to produce 12 times more IFN-y, 2 times more TNF-a, and 3 times less IL-4 
than cells isolated from healthy individuals (103). In addition, expression of the co-
stimulatory molecule, B7-2, was upregulated on lamina proprial mononuclear cells isolated 
from CD patients (121). The high level of this co-stimulatory molecule on lamina propria 
monocytes may be a factor in up-regulating T cell activation in the LP (121). 
In contrast to Crohn's disease, ulcerative colitis predominantly involves upregulation of 
cytokines such as IL-4, IL-5 and IL-10 suggesting Th-2-mediated colitis (59, 120). In 
oxazolone colitis, high levels of IL-4 and IL-5 and low to normal levels of IFN-y production 
support the theory that an uncontrolled Th-2 response may lead to a severe colitis that is 
characterized by the rapid onset of inflammation progressing to either complete recovery or 
death (14). Thus, it is different from Th-1-driven TNBS colitis in mice that develops more 
slowly and tends to persist in surviving mice (14). 
T helper Cells and Their key Regulatory Cytokines 
Th-1 cells 
Th-1 is the key regulator of type I immunity and IFN-y is the chief cytokine that orchestrates 
most of Th-1 activities. IFN-y upregulates MHC class II expression on macrophages (29, 42). 
Therefore, IFN-y boosts the effectiveness of T cell-macrophage interactions. IFN-y 
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upregulates the production of cytotoxic reactive oxygen and nitrogen intermediates from 
macrophages, and as a result increases the intracellular killing of microorganisms (140). 
There is a positive correlation between the upregulation of ROI and NOI in macrophages and 
the reduction of intracellular survival of pathogens in macrophages. For example, the 
survival of Toxoplasma gondii in macrophages was significantly decreased after treatment of 
macrophages with IFN-y (111). The decreased survival was correlated with an upregualtion 
of ROI and NOI production in these cells (111). IFN-y also stimulates cytotoxic T 
lymphocyte and NK cell generation in addition to positively regulating Th-1 differentiation. 
In addition, IFN-y accumulation induces the four cardinal signs of inflammation. IFN-y 
induces inflammation by upregulation of adhesion molecule expression on endothelial cells 
(82, 83, 91). IFN-y also causes vascular smooth muscle relaxation and endothelial retraction 
(70, 154), therefore, increasing the permeability of the epithelial layer (125). Thus, these 
effects on endothelial tissue could provoke the blood vessels to pass leukocytes, plasma 
proteins and inflammatory mediators to the site of inflammation where excess IFN-y is 
produced. As a result swelling, pain, erythema and heat generation will be prominent at the 
site where IFN-y is upregulated. These signs of inflammation are helpful in protection against 
many diseases but if left unchecked may lead to vigorous chronic inflammatory response as 
in the case for CD or ID. 
Th-2 cells 
Induction of Th-2 promotes humoral immunity including a strong antibody response. Th-2 
differentiation also induces mast cells and eosinophilic growth and differentiation factors 
(98), inhibition of several macrophage functions such as nitric oxide and reactive oxygen 
intermediates production (3, 12, 13, 61), and down-regulation of the Th-1 response. The Th-2 
regulatory cytokines include IL-4, IL-5, and IL-10 (51, 109). IL-4 is critical in driving Th-0 
towards Th-2 differentiation (68). It also specifically inhibits EFN-y-production from Th-1 
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cells (128) and promotes the proliferation of activated human B lymphocytes (26) as well as 
the secretion of immunoglobulins such as IgGl, IgG4 or IgE (60, 146). IL-5 is associated 
mainly with eosinophilic inflammation (182) but also acts as a late factor in B cell 
differentiation causing an enhancement of IgM, IgG or IgA production (138). 
IL-10 is considered an immunosuppressive cytokine that can be produced by several cell 
types including activated Th-2 cells, B cells, and macrophages (37, 38). LPS-induced 
production of IL-10 from monocytes and macrophages is enhanced in the presence of TNF-a 
and suppressed in the presence of IL-4, IL-10, IFN-y and TGF-(3 (25, 38, 130, 183). The 
production of IL-10 in PHA-activated T cells (i.e., CD4+ and CD8+ T cells) was enhanced in 
the presence of IL-12 (34). Stimulation of pure CD4+ and CD8+ T cells isolated from PBMC 
by positive selection with various concentrations of IL-12 and in the presence of PHA 
resulted in at least a 3-fold increase in the amount of IL-10 produced (34). This study 
suggests that IL-12 and IL-10 are key regulatory cytokines that manipulate the outcome of T 
helper cell activation. IL-12 produced from monocytes might play an early role in the 
immune response by generating and activating Th-1 responses, but may later stimulate the 
production of IL-10. This is also supported in the study of cytokine production kinetics in 
human monocyte cell cultures after LPS stimulation (38). Following mitogen activation of 
PBMC, pro-inflammatory cytokines such as TNF-a, IFN-y and IL-12 were upregulated in 
early stages of culture (i.e., 4-8h) followed by detection of IL-10 after 7 hours of incubation 
with a peak production of IL-10 at 24-48h (38). 
IL-10 is also produced by both Ly-1+ B-l cells and Ly-1" conventional B cells but B-l cells 
are more extensive producers of IL-10 (62, 122). In mice, this cytokine positively regulates 
the growth and development of the B-l cell lineage, (78) and, interestingly, rIL-12 stimulates 
B-la cells (CD5+ B cells) in splenocyte cell cultures to express high levels of IL-10 mRNA 
(178). IL-10 interrupts the expansion of memory B cells in the secondary lymphoid organs 
germinal center (GC) (24, 197). The absence of CD40L stimulation and the presence of IL-
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10 drives B cell development and differentiation in the GC towards plasma cells while the 
absence of IL-10 leads to the development of memory B cells (24, 197). 
IL-10 is considered as an important immune regulatory cytokine that controls the shift of the 
immune response from a pro-inflammatory to an anti-inflammatory response. IL-10 
decreases the production of a broad spectrum of pro-inflammatory cytokines such as IL-1, 
IL-6, GM-CSF, G-CSF, M-GSF, MIP-1 and -2, TNF-a RANTES and IL-12 from monocytes 
(40). IL-10 specifically inhibits IFN-y synthesis by T cells (53) and NK cells (75). It also can 
inhibit the microbicidal activity as well as nitric oxide production of IFN y treated 
macrophages that is essential for the control of intracellular pathogens such as listeria, 
leishmania and mycobacteria (61). In contrast to the inhibitory effect of IL-10 on 
monocyte/macrophage activities, this cytokine upregulates the phagocytic ability of these 
cells through an increase in the expression of FcR's such as CD 16 and CD64 (162). 
T regulatory cells 
IL-10 induces the differentiation of regulatory T cells (66, 67). It inhibits the synthesis of 
CD80, CD86 and ICAM-1 which decreases the strength of interactions between APC's and T 
cells leading to weak stimulatory effects forT cell activation (20, 45, 189). In a situation like 
this where effective APC's are absent, IL-10 can extend its inhibitory effects on T cells 
causing a suppression of IL-2 and TNF-a production from CD4+ cells (39, 41). In mice and 
humans, such T cells are designated T regulatory cells (Trl) (66). These anergic T cells are 
unresponsive to antigen stimulation so they do not proliferate and produce low quantities of 
cytokines (i.e., IL-5 IFN-y, TGF-(3 and TNF-a) compared to undifferentiated Th-0 cells (67). 
These cells are also different from Th-0 in their ability to produce very high levels of IL-10, 
low quantities of IL-2 and no IL-4 (66). 
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Th-3 cells 
Regulatory T cells generated as a result of oral tolerance produce high levels of TGF-(3 and 
variable amounts of IL-4 and IL-10 upon activation (22). These cells are recognized as Th-3 
cells (184, 185). While the induction of Th-3 is favored in a Th-2 environment, Th-1 
conditions inhibit their induction. Therefore, conditions that favor high IL-4, IL-10, TGF-(3 
production and/or low IFN-y production greatly enhance TGF-(3 production from Th-3 cells 
(184, 185). 
The most recent study evaluating the effects of TGF-|3 effect on T cells demonstrated that the 
effect on T helper cells is dependent upon T cell differentiation and activation conditions 
(64). Briefly, in the case of suboptimal antigen stimulation of T cells, the presence of TGF-(3 
resulted in the inhibition of T cell activation and proliferation. In contrast, with optimal 
antigen activation, exposure of cells to TGF-(3 before they differentiate into either Th-1 or 
Th-2 causes a halt in their activation and results in the development of cells carrying neither 
Th-1 or Th-2 phenotype properties but still able to produce IL-2 (64). If T cells receive 
proper activation signals before getting exposed to TGF-(3 they differentiate normally 
towards either Th-1 or Th-2 (64, 136). If TGF-(3 is present with these fully differentiated 
cells along with IL-2, clonal expansion will occur. The inhibitory effect of TGF-(3 in the 
early stages of cell activation is more prominent for Th-2. IL-4 could not reverse the 
inhibitory effects of TGF-(3 but the development of Th-1 cells was possible with the addition 
of IFN-y (96,156). 
Therefore, the inhibitory effect of TGF-(3 on Th-1 differentiation could be overcome in the 
presence of IFN-y (136). Despite this effect, TGF-(3 was still able to inhibit the production of 
cytokines, specifically IFN-y from these fully differentiated Th-1 cells (87, 99). In contrast, 
cytokine production from fully differentiated Th-2 cells is not inhibited by TGF-(3 (99, 136). 
The inhibitory effect of TGF-(3 on both resting Th-1 and Th-2 is due to high expression of 
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TGF-(3 receptors on their surfaces (31). In contrast, T cell activation causes a down 
regulation of TGF-(3RII expression, which can be restored in the presence of IL-10 (31). 
In addition to Th-3 cells, tissue macrophages (e.g., alveolar) and peripheral monocytes 
produce TGF-|3 (6). Similar to T helper cells, TGF-(3 also has both inhibitory and stimulatory 
effects on macrophage activities. Low TGF-J3 concentrations induce chemotaxis of human 
peripheral blood monocytes to the site of inflammation while high TGF-(3 concentrations 
activate these monocytes and causes increased expression of TNF-a and IL-1(3 mRNA (21, 
180, 181). TGF-(3 also activates the phagocytic ability of monocyte/macrophage through 
upregulation of CD16 expression on their surface (187). The effect of TGF-(3 on tissue 
macrophages is mainly suppressive. This includes increased expression of IL-1 receptor 
antagonist (170), and limited ROI and RNI production from macrophages activated with LPS 
or IFN-y (12). 
Cytokines Involved in Defense and Pathology of Mycobacterial Infection 
Mycobacterium tuberculosis and M. bovis 
Tuberculosis primarily affects the lower respiratory system and is characterized by a chronic 
productive cough, low-grade fever, night sweats, and weight loss. Mycobacteria enter the 
lung alveoli by airborne transmission. They resist destruction by alveolar macrophages and 
multiply, forming the primary lesion. Exposure to mycobacteria may not establish disease 
because of the complete and immediate destruction of bacteria by host innate immunity 
(173). 
Recognition of mycobacteria by phagocytes is an important step in disease progression and 
bacterial destruction. Elevated levels of circulating factors such as plasma LPS-binding 
protein has been noted in patients with active tuberculosis (80). This resulted in enhanced 
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responsiveness of macrophages to LPS and lipoarabinomannan (LAM), a major 
mycobacterial cell wall component which resembles LPS (52). Through toll-like receptors 
(TLR 2 and TLR 4), which are an important mediator of microbial recognition by 
macrophages and dendritic cells (179), M. tuberculosis cell lysate or soluble cell wall 
lipoprotein components can induce IL-12 production (16). Failure to destroy the bacteria 
after the initial exposure by a component of innate immunity results in chronic infection. 
This infection will then be either contained (150) through development of a protective 
immune response (i.e., latent infection) or proceed into active tuberculosis within one to three 
years (155). Then the fate of the latent infection is either recovery or reactivation and 
development of tuberculosis. 
Replication of bacteria inside the macrophage results in production of cytokines that initiate 
and activate the inflammatory response to mycobacterial infection. These cytokines mediate 
the cross-talk between macrophages and lymphocytes and result in granuloma formation that 
consists of macrophages, T cells, and granulocytes (141). Although mycobacteria continue to 
survive within the granuloma (i.e., tuberculous lesion), the granuloma formation in 
tuberculosis is essential in containing or segregating the infection from spreading to more 
healthy tissues (46). When the equilibrium between the host immunity and the bacteria 
within the tuberculous lesion weakens, release of the mycobacteria from the granuloma will 
result in either more granulomatous lesions or more commonly severe disseminated 
uncontained infection (46, 141). 
Pro-inflammatory cytokines produced in response to mycobacteria are often associated with 
the contained form of infection. For example, infection of APC with mycobacteria or 
stimulation of APC with mycobacterial products induces TNF-a production (69, 172). TNF-
a production regulates several factors involved in containing the mycobacterial infection 
such as granuloma formation and macrophage activation (86, 169). In addition, DL-1 is 
spontaneously released from bronchoalveolar lavage cells obtained from the infected lung of 
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TB patients (94). Studies with IL-1 knockout mice or IL-1R type I deficient mice indicated 
that the absence of IL-1 as well as its effect (i.e., IL-1R deficiency) causes an abrogation of 
granuloma formation allowing M. tuberculosis to replicate (79, 192). Almost 65% of the 
mice in the experiment with IL-1 receptor deficiency died, and the remaining animals 
become severely ill (79, 192). Another important immune regulatory cytokine involved in 
defense against M. tuberculosis is IL-12. Interleukin-12 is found to be elevated in the 
granulomas and in the lung infiltrates of tuberculosis patients (18). The absence of bioactive 
IL-12 resulted in the inability of IL-12 knockout mice to control bacterial growth in the lung, 
spleen and liver (30). The absence of this cytokine is also associated with a reduction of 
mRNA expression for both IFN-y and TNF-a and subsequent amelioration of macrophage 
activity represented by the reduction of mRNA expression of inducible nitric oxide synthase 
(30). 
The involvement of IFN-y in tuberculosis is well studied and evidence suggests that this 
cytokine is the most important pro-inflammatory cytokine in defense against M. tuberculosis. 
Recombinant IFN-y addition to macrophage cell cultures enhanced the ability of these cells 
to limit M. tuberculosis and M. bovis growth (54, 134). Continuous infusion of rIFN-y to 
BALB/c mice via osmotic micropumps leads to an increase in their resistance to a lethal dose 
of M. tuberculosis as well as to decreased bacterial growth in spleen, liver and lung (43). 
Conversely, infection of IFN-y knockout mice with a sublethal dose of M. bovis or M. 
tuberculosis lead to an increase in mortality and increased bacterial numbers recovered from 
spleen, liver and lung (29, 35). Measurement of IFN-y production in response to in vitro 
mycobacterial antigen stimulation is also used as an indicator of M. tuberculosis infection 
(174). For example, whole blood cultures obtained from individuals with positive tuberculin 
skin test stimulation with PPD results in higher levels of IFN-y than stimulation of blood 
cultures obtained from individuals with negative tuberculin skin test. This selective 
production of IFN-y is present only if cells are stimulated with mycobacteria purified protein 
derivative, not when cells were stimulated with mycobacterium whole cell sonicate. The 
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latter stimulation induces IFN-y production in both tuberculin skin test positive and negative 
individuals. 
A more recent study indicated that M. tuberculosis has developed a mechanism by which it 
can block the effects of IFN-y (164). This inhibition is mediated by interfering with the IFN-y 
signaling pathway. One important step in IFN-y signaling is the translocation of STAT1 
homodimers into the nucleus (63). This translocated dimer interacts with the basal 
transcriptional apparatus in the nucleus through the CBP/P300 family of transcriptional 
coactivators which are essential for effective IFN-y signaling (196). The presence of M. 
tuberculosis disrupts this interaction and causes further disruption through a reduction in the 
ability of IFN-y treated macrophages to kill other intracellular organisms such as Toxoplasma 
gondii (164). The presence of IFN-y in tuberculosis patients indicates a struggle between the 
immune system and the mycobacteria. The result is either a chronic latent infection or 
reactivation of infection along with a failure of the immune system and, thus, disease 
progression. Disruption of IFN-y signaling may explain why the elevated IFN-y production in 
M. tuberculosis does not clear the infection. Perhaps the inhibition of macrophage function 
due to reduced response to IFN-y is one mechanism by which mycobacteria avoid destruction 
(55). 
The survival of mycobacteria in macrophages likely involves more than one factor. The 
presence of the anti-inflammatory cytokines that counteract, inhibit and manipulate the effect 
of pro-inflammatory cytokines might be one mechanism for intracellular survival. Infection 
of monocytes isolated from human PBMC with M. tuberculosis induces the production of IL-
12, TNF-a and IL-10 (57, 145). The early induction of IL-10 (3-6h) does not affect the 
ability of monocytes to co-express and release IL-12 since neutralization by addition of anti-
IL-10 monoclonal antibody to the culture does not affect IL-12 production (57). Conversely, 
excess levels of IL-10 present before and during the first few hours of tuberculosis infection 
decreased IL-12 production and delayed its expression for 6 hours (57). These data suggest 
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that in the very early phase of monocyte exposure to M. tuberculosis infection and when the 
bacterial load is low, IL-12 production is optimal and is not affected by IL-10 co-induction. 
Later, when endogenous IL-10 expression is upregulated it causes the inhibition of IL-12 
production with the most pronounced effect on the newly recruited monocytes. However, the 
recruitment of monocytes is accompanied by the recruitment of T cells. The presence of T 
cells could overcome the inhibitory effect of IL-10 on IL-12 production through IFN-y 
release as IFN-y dramatically enhances IL-12 production in monocyte cultures infected with 
M. tuberculosis (57). 
Evidence obtained from studies with IL-10 transgenic mice and IL-10 knockout mice 
indicates that IL-10 is often associated with immune suppression in mycobacterial infection 
and with the replication of mycobacteria. One study showed that intravenous injection of IL-
10 transgenic mice with Calmette-Guerin bacillus (BCG) resulted in dissemination of the 
bacteria throughout the body that persisted over the course of the experiment (12 weeks) 
(112). Interestingly, the excess IL-10 present in transgenic mice did not interfere with the 
ability of splenocytes to produce IFN-y in response to BCG stimulation (112). Thus, it might 
be that an imbalance favoring IL-10 over IFN-y production during mycobacterial infection 
results in reduced macrophage activation and subsequent decreased destruction of 
mycobacteria. In IL-10 knockout mice, infection with BCG resulted in a lower burden of 
bacteria in spleen and liver in the first two weeks of the experiment (113). Macrophages 
isolated from the peritoneum of these mice produced increased levels of inflammatory 
mediators such as NO, prostaglandin and TNF-a compared to wild type mice. When IL-10 
was added to the cell cultures the increased production of these mediators was clearly 
reversed. The limited resistance to mycobacteria infection in the IL-10 knockout mice during 
early infection (first two weeks) suggests that other factors such as TGF-p or IL-4 might play 
a similar role to IL-10. 
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TGF P is upregulated during tuberculosis and at the site of active disease (166). Moreover, 
neutralization of TGF-(3 with anti-TGF antibody or with natural TGF-[3 inhibitors (e.g., 
decorin and latency-associated peptide (LAP)) is reported to improve T cell responses in 
PBMC cultures obtained from patients with pulmonary tuberculosis (71). PBMC culture 
from patients with active tuberculosis spontaneously produced high levels of TGF-(3 (167). 
Moreover, tissues from patients with active tuberculosis stained for intracellular TGF-(3 
revealed that this cytokine was mainly present in Langhans giant cells and to a lesser extent 
in the epithelioid cells present in the granulomas (167). A comparison of alveolar 
macrophage and monocyte cell cultures after LPS, PMA and Con-A stimulation revealed that 
alveolar macrophages have a reduced ability to produce TGF-J3 (168). This suggests that 
TGF-(3 present within the granulomas may be a result of recruitment and activation of 
monocytes which originating from the blood. 
TGF-(3 has also been shown experimentally to enhance the intracellular growth of M. 
tuberculosis in human monocytes (73). After infection of monocytes with M. tuberculosis, 
production of TGF-p in cell culture supernatant was low in the first 24 hours of incubation 
(<50 pg/ml) then increased up to 8-fold after 4 days in culture (73). This increased 
production of TGF-(3 was accompanied by an inability of monocytes in culture to control 
growth of M. tuberculosis. Neutralization of TGF-(3 resulted in a 3-fold reduction of the 
intracellular replication of M. tuberculosis by day 7 (73). Incubation of monocytes with 10 
ng/ml of rTGF-(3 followed by infection with M. tuberculosis resulted in at least 3-fold 
increase in the number of CFU recovered from the cell lysate after 7 days in culture (i.e., 32 
X 104 CFU/ml of cell lysate obtained from cells cultured with medium control compared to 
112 X 104 CFU/ml in cells treated with rTGF-[3). In this same study, addition of TNF-a to 
monocyte cultures after M. tuberculosis infection caused a 4-fold reduction in the CFU 
obtained from the cell lysate between day 4 and 7 (73). When TGF-(3 was co-cultured with 
TNF-a it reversed this effect resulting in a 2.9 fold increase in viable bacteria recovered (73). 
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Similar experimental results were obtained when infected monocytes were cultured with 
IFN-y alone or in combination with TGF-(3 (73). 
Finally, the interaction between IL-10 and TGF-(3 in M. tuberculosis infection appears to be 
synergistic (126). One study demonstrated that upregulation of TGF-(3 specifically 
upregulated IL-10 production and that these two cytokines overlap with each other to 
potentiate their downregulatory effect on M. tuberculosis-induced T cell production of IFN-y 
(126). An interaction between TGF-(3 and IL-4 also occurs, but interestingly the presence of 
both cytokines directs the development of T cells towards a Th-1 profile of response (i.e., 
CD8+ type I cells) (48). TGF-[3 alone in the absence of IL-4 suppresses the development of 
CD8+ type I cells leading to the reduced production of IFN-y (48). When both IL-4 and TGF-
(3 were present in the lymph node cell culture of the CD8+ T cells, a strong Th-1 response 
characterized by high production of IFN-y was noted (48). In tuberculosis, the role of IL-4 is 
in great dispute with suggestions ranging from the implication that this cytokine is involved 
in disease manifestation to the suggestion that its association with the tuberculosis is only a 
consequence of infection rather than a causative factor (173). 
Mycobacterium leprae 
Leprosy is an infection of the skin, peripheral nerves, and mucous membranes, progressing to 
lesions of hypopigmentation, and loss of sensation particularly in the cooler areas of the body 
(129). As in tuberculosis, the spectrum of leprosy pathogenesis ranges from localized 
tuberculoid, paucibacillary leprosy with strong cell-mediated immunity to disseminated 
lepromatous multibacillary leprosy, with loss of specific cell-mediated immunity (137). 
Cytokine involvement in leprosy is quite similar to tuberculosis. Briefly, the protective 
immunity that contains and localizes the disease in the tuberculoid form of leprosy is 
mediated by a Th-1 type of response represented by IFN-y production (5, 117, 193). 
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Cytokines such as TGF-(3, IL-10 and IL-4 are mainly associated with lepromatous leprosy 
and disseminated disease (5, 65, 114, 144, 193, 194). 
Mycobacterium avium and Mycobacterium intracellular 
Mycobacterium avium Complex (MAC) disease is among the most common bacterial 
infections in people with AIDS. MAC bacteria were identified in the blood of 43% of people 
within two years of diagnosis with AIDS (2). MAC is the term for two related bacteria: 
Mycobacterium avium and Mycobacterium intracellulare (MAI) (19). The most common 
infection symptoms in MAI infection are persistent fevers plus night sweats, loss of appetite, 
weight loss, tiredness or worsening diarrhea (2). 
Cytokine involvement in MAI infection follows a similar pattern of other mycobacterial 
infections including M. tuberculosis. Macrophages activated with IFN-y or TNF-a can 
restrict M. avium growth (4). PBMC from healthy people that are exposed to MAC infection 
(i.e., positive skin test to M. avium) secreted increased levels of IFN-y in their cell culture 
supernatants while PBMC cultures from HIV patients with active MAC infection produced 
high levels of IL-10 and low levels of IL-12, IFN-y and TNF-a (176). Similar to other 
mycobacterial infections, TGF-(3 has an immunosuppressive role in M. avium infection. Mice 
injected weekly with 1 (ig of rTGF-(3 intraperitoneal^ and intravenously infected with 105 
CFU of M. avium had a 3 log increase in M. avium recovered from the spleen after 80 days of 
infection compared to mice not treated with TGF-(3 (44). Treatment of mice receiving rTGF-
(3 with an anti- TGF-J3 monoclonal antibody lead to a decrease in the numbers of CFU 
recovered from these mice (i.e., 0.7-0.9 log decrease at day 80) compared to mice received 
rTGF-(3 alone (44). 
In summary, the involvement of anti-inflammatory and pro-inflammatory cytokines in 
immunity or the pathology of mycobacterial infection appears to involve a wide network of 
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cytokines. The effect of each cytokine alone might imply effects ranging from increased 
protection to increased susceptibility to mycobacterial infection. Yet the interaction of these 
cytokines during infection may yield similar, different or amplified results depending upon 
how they regulate one another. 
The Immune Response to Mycobacterium Paratuberculosis Infection 
Mycobacterium paratuberculosis the causative agent for Johne's disease generally colonizes 
in the lower part of the small intestine (108). Within a few hours after M. paratuberculosis 
ingestion, the bacteria cross M cells lining the Peyer's patches and can be detected in the 
subepithelial macrophages (108). The precise mechanism of M. paratuberculosis entry into 
macrophages is still unknown. Generally, mycobacteria could enter macrophages through 
TLR-2 which provoke cell activation and production of TNF-a (107, 165, 171). Complement 
receptors could also mediate an opsonic and non-opsonic phagocytosis (72) and activation or 
inhibition of macrophages activities after phagocytosis depending upon the complement 
receptor involved. For example, antigen uptake through CR3 is not associated with a 
respiratory burst and results in decreased IL-12 production by macrophages (104, 191). 
Uptake through the mannose receptor also facilitated phagocytosis of mycobacteria but did 
not elicit macrophage activation (e.g., phagosome maturation) (7). Therefore, the selective 
entry into macrophages that mycobacteria may create an environment that does not trigger 
macrophage defense mechanisms such as oxidative burst. 
In response to this infection the host immune response initiates a series of immune defense 
mechanisms to deal with the M. paratuberculosis infection. The host's immune system 
responds to M. paratuberculosis infection by recruiting more macrophages to the site of 
infection as the number of macrophages present in the ileum of naturally infected cows was 
reported to be higher than non-infected control animals, with neutrophils being the 
predominant phagocytic cells in the latter group (95). Based upon information from other 
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mycobacterial diseases, it has been suggested that the host's immune system responds to M. 
paratuberculosis infection by recruiting more macrophages and lymphocytes to the site as 
well as by activation of immune cells such as gamma delta T cells, CD4+ T cells and 
cytolytic CD8+ T cells (32). Infiltration of infected tissues with lymphocytes and 
macrophages leads to thickening of the intestine and the mucosal surface becomes corrugated 
in appearance over time . Thus, the ileum loses its thin and pliable appearance due to the 
influx of numerous lymphocytes and macrophages (23, 32). The draining lymph nodes such 
as the mesenteric and ileocecal lymph nodes will become enlarged. Lesions in 
paratuberculosis infection are mainly due to accumulation of macrophages population in the 
intestinal wall (23, 95). 
During this ongoing interaction between host immunity and the M. paratuberculosis infected 
macrophages, a deviation from the proper immune response against this intracellular 
infection might arise and disrupt the host's attempts to contain the disease. This might lead to 
progressive failure of the macrophages ability to kill the bacteria, increase the ability of M. 
paratuberculosis to replicate and eventually result in death of the macrophages. 
Similar to other mycobacterial infections, M. paratuberculosis is an intracellular pathogen 
that once phagocytized by macrophages can evade the aggressive host immune reaction 
generated inside these cells. M. paratuberculosis resides inside phagosomes that retain 
features of the early phagosomal compartment. Experimental infection of the J774 mouse 
macrophages cell line with M. paratuberculosis has shown a decrease in phagosomal 
acidification (23, 74, 89). Macrophage activation with recombinant IFN-y and LPS lead to 
increased acidification and maturation of phagosomes containing M. paratuberculosis (74). 
There was a significant decrease in the percentage of M. paratuberculosis surviving in the 
macrophage cell line treated with IFN-y and LPS compared to non-treated cells (74). In 
addition, the colonization of M. paratuberculosis in the late phagosomal cell compartments 
after treatment with IFN-y and LPS increased the bacterial exposure to more hostile 
34 
environment present in these late phagosomes (74). This suggests that activated macrophages 
are more effective in M. paratuberculosis killing than monocytes or inactive macrophages. 
Moreover, this result provides further evidence of the importance of IFN-y in macrophage 
activation and maturation. In addition, treatment of M. paratuberculosis-infected bovine 
monocytes with IFN-y increased the release of nitric oxide by macrophages (198). 
The stages of Johne's disease reflect an ongoing struggle of host immunity. The induction of 
IFN-y that is usually present in the contained stage of disease represents an activation of the 
host cell-mediated immune response. Animals in the excretory subclinical stage are reported 
to have high IFN-y locally at the site of infection in tissues such as ileum and mesenteric 
lymph nodes (158). IFN-y gene expression in the clinically infected cows is reported to be 
higher than in the control non-infected animals (95) but the highest gene expression of this 
cytokine was reported in tissues obtained from subclinical animals (158). Gene expression of 
other proinflammatory cytokines such as IL-la, IL-1(3 and IL-6 was elevated in M. 
paratuberculosis-'mfected animals with clinical disease compared to control animals (95). In 
sheep, TNF-a, IL-1(3 and IL-6 gene expression were also elevated in the intestinal tissues 
obtained from animals in the multibacillary stage of the disease (1). Nevertheless, TNF-a 
gene expression in cattle intestinal tissues was not different between M. paratuberculosis 
infected and non-infected animal groups (95). Moreover, PBMC cultures from subclinical 
cows stimulated with M. paratuberculosis antigens produced higher amounts of IFN-y 
compared to clinical and healthy cows (148, 149). In addition, in vitro production of TNF-a 
from PBMC after stimulation with M. paratuberculosis whole cell sonicate followed the 
same pattern of IFN-y production where it was noted to be elevated in the subclinical and not 
in the clinically infected or control groups (149). In one study, TNF-a had a dual effect on 
M. paratuberculosis survival where stimulation of a mouse macrophage cell line with high 
doses of rTNF-a (i.e., 4000 IU/ml) suppressed the intracellular survival of M. 
paratuberculosis yet moderate doses (i.e., 10-1000 IU/ml) resulted in increased survival and 
replication of M. paratuberculosis within cells (147). This information indicates that 
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macrophages at the site of infection are active (i.e., high IL-1(3, IL-6 production) but it seems 
that the interaction with the surrounding immune cells may be impaired. This is demonstrated 
by the decrease in IFN-y gene expression noted after animals progresses from subclinical to 
the clinical stage of disease. 
Most of the other information about the interaction between M. paratuberculosis and the 
immune system is speculative and mainly based on information derived from other 
mycobacterial diseases. There is strong evidence that the cell mediated immune response 
represented by high IFN-y is fully functional in the subclinical stage of the disease (148, 149, 
158). This response is down-regulated when animals progress to the clinical stage of the 
disease when other proinflammatory cytokines such as IL-1(3 and IL-6 become elevated (95, 
149). This may suggest that an immune modulatory response surmounts the effective cell-
mediated immunity represented by the presence of IFN-y presence in the subclinical animals. 
In other mycobacterial diseases such as M. tuberculosis infection, both TGF-(3 and IL-10 
facilitated the suppression of mononuclear cell function and decreased IFN-y expression 
(126). Recently, two new reports correlated IL-10 presence with clinical stage of M. 
paratuberculosis infection. The first study reported that stimulation of PBMC cultures 
obtained from two clinical Johne's cows with Con A upregulated the gene expression of IL-
10 more than in cells from non-infected and subclinical Johne's cows (33). The other study 
reported that after stimulation of PBMC cultures obtained from two non-infected cows with 
live M. paratuberculosis, IL-10 gene expression was significantly elevated at all time points 
(i.e., 6h, 24h and 72h) (186). In regards to TGF-(3, no single report addresses the role of this 
important immune regulatory cytokine in bovine M. paratuberculosis infection. 
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CHAPTER TWO. DEREGULATION OF TGF BETA AND IL-10 IN 
COWS WITH CLINICAL JOHNE'S DISEASE 
A paper prepared for submission to Veterninary Immunology and Immunopathology 
M. S. Khalifeh, T. L. Bosworth and J. R. Stabel 
Abstract 
Johne's disease is an important disease that results in great economic losses for both dairy 
and beef production worldwide. The disease progresses through distinct stages including a 
subclinical stage and a clinical stage that is characterized by progressive symptoms 
associated with chronic shedding of Mycobacterium paratuberculosis in the feces along with 
severe diarrhea and concomitant weight loss. The host immune response to M. 
paratuberculosis is paradoxical in that there is a strong cell-mediated immune response 
during the subclinical stage and a strong humoral response during the clinical stage of the 
disease. It is possible that immune modulation of the cell-mediated immune response in 
paratuberculosis may play an important role in disease progression. We hypothesized that the 
clinical stage of Johne's disease is mediated by the presence of cytokines such as 
transforming growth factor-beta (TGF-(3) and interleukin-10 (IL-10) that may be 
accompanied by the downregulation of IFN-y gene expression. In the present study, tissue 
samples were collected from the ileum, ileal-cecal junction, ileal-cecal lymph node, and 
mesenteric lymph nodes of healthy, subclinically or clinically infected cows. The gene 
expression of TGF-(3, IL-10, and IFN-y mRNA in these tissues was determined by 
quantitative competitive RT-PCR. The results show that TGF-|3 and IL-10 mRNA levels are 
higher in cows that have progressed to the clinical stage of disease compared to subclinically 
infected or healthy cows, However, IFN-y expression was higher in subclinically infected 
cows. A change in the balance of cytokines at the site of infection may significantly 
contribute to the ability of the host to control M. paratuberculosis infection. 
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Introduction 
M. paratuberculosis is the causative agent of Johne's disease, a chronic enteritis 
characterized by intermittent diarrhea, weight loss, and eventual death. Animals become 
infected at an early age through ingestion of contaminated feces and milk; however, fetal 
infection is also possible in dams with advanced disease (Cocito et al. 1994; Sweeney et al. 
1992a; Sweeney et al. 1992b). Clinical disease generally does not become apparent for 3 to 5 
years post-exposure; however, significant economic losses may be incurred due to a decrease 
in milk production and reproductive problems, leading to premature culling of infected 
animals from the herd (Hutchinson 1996). 
As in other mycobacterial infections, a cell-mediated immune response is vigorously active 
during the early stages of disease. This type of immunity limits the disease progression and is 
characterized by elevated antigen-specific IFN-y production (Stabel 1996; Stabel 2000). 
Animals in the subclinical stage of disease generally shed low numbers of bacteria in their 
feces and have low antibody titers to M. paratuberculosis. As infection progresses to a more 
clinical state, bacterial shedding in the feces is increased, serum antibody titers increase and 
IFN-y production declines (Stabel 1996). 
It is unclear what mechanism(s) initiate the progression from subclinical to clinical stage of 
disease. It is probable that activation of an immune response that antagonizes the cell-
mediated response is responsible for the change in the ability of the host to contain the 
infection. Immunomodulatory cytokines (e.g., TGF-(3 and IL-10) have been identified in the 
late stages of mycobacterial infection and are associated with increased intracellular 
replication of mycobacteria (Flesch et al. 1994). It has been further demonstrated that these 
two cytokines actively interfere with IFN-y production, an essential factor for containment of 
infection (Othieno et al. 1999). 
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Although the effects of natural or experimental M. paratuberculosis infection on IFN-y 
production at different stages has been addressed in several studies (Stabel 1996; Stabel 
2000; Sweeney et al. 1998), there is no published information to date on the expression of IL-
10 and TGF-(3 in cattle infected with M. paratuberculosis. We hypothesize that the decrease 
in IFN-y production in the clinical stage of Johne's disease is accompanied by an increase in 
the production of the regulatory cytokines, IL-10 and TGF-P- In the present study, we 
performed competitive RT-PCR for quantitation of cDNA levels of IFN-y, IL-10 and TGF-(3 
at the site of infection (i.e., ileal-cecal node, mesenteric lymph node, ileum, and ileal-cecal 
junction) in subclinically and clinically infected cows and compared this to expression of 
these cytokine genes in healthy, non-infected cows. 
Materials and Methods 
Tissue collection and preparation: The number of tissues obtained from Holsteins cows 
within each group is presented in Table 1. The non-infected control cows (n=7) were 
characterized by repeated negative fecal cultures performed quarterly over a 3-5 year period. 
In addition, these animals were negative on any serologic assays (i.e., production of antibody 
specific for M. paratuberculosis and IFN-y) performed during that period. Positive cows 
were classified as clinically infected on the basis of high level of fecal M. paratuberculosis 
shedding (> 100 CFU/g) and clinical signs of disease such as intermittent diarrhea, rapid 
weight loss, and inappetence in the period immediatly prior to obtaining the tissue samples 
while Subclinically infected animals shed low numbers of M. paratuberculosis (< 10 CFU/g 
feces). Prior to necropsy, animals were sedated with an intravenous injection of xylazine (0.1 
mg/kg) and euthanized with an overdose of pentobarbital. Ileal samples of all cattle were 
collected at necropsy by removing the last 6 inches of the distal ileum proximal to the 
ileocecal junction. Other tissue samples, ileocecal junction, ileocecal lymph node, and 
mesenteric lymph node were also collected at necropsy from each cow. Tissues were 
immediately snap frozen in liquid nitogen and then stored at -80 °C until analyzed. Ileal 
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tissues from clinically infected cows stained positive by Ziehl-Neelsen stain indicating the 
presence of high numbers of acid-fast bacilli within the cytoplasm of macrophages. The 
macrophages were present in the lamina propria and submucosa most frequently. Tissues 
from subclinically infected cows had very few acid-fast bacteria and non-infected control 
cows were negative for organisms in their tissues. 
RNA Extraction and Competitive RT-PCR: Total RNA was extracted from each tissue 
cell lysate preparation using the TRIzol method (Gibco, Grand Island, NY). RNA was 
dissolved in diethyl pyrocarbonate (DEPC) (Sigma, St. Louis, MO) treated sterile water and 
quantitated at A260 nm with a spectrophotometer. The quality of extracted RNA was also 
assessed by running the RNA on 1% native agarose gel. For cDNA synthesis from RNA, 6 
|ig of total RNA was added to a final volume of 60 [il mixed with 3 pil of poly dT primer 
(pDT15) at 0.5 |ig/|il (Roche diagnostics, Mannheim, Germany), and heated at 72°C for 10 
min then snap cooled on ice. The reverse transcriptase reaction was performed by adding 5 jil 
of RNase inhibitor at 40 U/ |il (Roche), 7.5 |il of 10 mM PCR nucleotide mix (dNTP) 
(Roche), 5 ill of 20U/ (il Molony murine leukemia virus reverse transcriptase (M-MuLV 
RT), 15 jil of the supplied 5X M-MuLV RT cDNA synthesis buffer (Roche) and 54.5 fj.1 of 
DEPC treated water. Reaction tubes were then heated at 45°C for 1 hr followed by heating at 
95°C for 5 min to inactivate the reverse transcription enzyme and stored at -20°C until used 
for quantitative analysis. 
Bovine IL-10, IFN-y, and TGF-J3 mimic cDNA fragments were produced by construction of 
composite primers designed to amplify a specific sequence on these cytokines as well as a 
short sequence of cDNA specific to the mimic fragments (Figure 1). The mimic fragment is 
an exogenous template that is used as an internal standard in PCR. It shares the same target 
primer sequence but has a completely different intervening sequence. The exogenous 
templates (i.e., the mimic fragments) were produced via amplification of a heterologous 
DNA fragment from Clontech (Palo Alto, CA) with each cytokine mimic primer (Figure 1 
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right) by 35 cycles of denaturation at 95°C for 1 min, primer annealing at 58°C for 1 min and 
extension at 72°C for 1 min, followed by 1 cycle of extension at 72°C for 10 min in a Perkin-
Elmer Cetus thermal cycler (Noralk, CT). Concentration of the constructed mimic for each 
cytokine was determined by spectophotometric absorption at 260 nm. 
Primer pairs for IFN-y and TGF-(3 were selected from previous reports (Cerretti et al. 1986; 
Plath et al. 1997). IL-10 primers were selected in house by MacVector (Genetics Computer 
Group, Inc, Madison, WI). IFN-y target product size was 270 bp and the corresponding 
mimic product size was 409 bp, TGF-(3 target product size was 223 bp and the corresponding 
mimic product size was 439 bp; IL-10 PCR product was 288 bp and the corresponding mimic 
product size was 135 bp. A second round of PCR was performed using cytokine target 
primers (Figure 1 left). Each reaction contained a fixed target concentration (1 jig) and the 
mimic fragment concentration was serially diluted (1:10) starting at 1 pg/j-tl - 10 5 pg/p.1 for 
the IFN-y mimic, 50 pg - 5 X 10~3 pg/|il for the TGF-(3 mimic and 0.05 pg/jj.1 - 5 X 10"6 pg/jul 
for the IL-10 mimic. Each PCR reaction contained 10 p,l of 10X ampliTaq gold PCR buffer II 
(Applied Biosystems, Foster city, CA),15 |il of 25 mM MgC12 solution (Applied 
Biosystems), 2 |il of 10 mM PCR nucleotide Mix (dNTP) (i.e., 0.4 mM per reaction) and 0.5 
mM of upstream and down stream primers for a given cytokine (IDT,Coralville, IA) (Figure 
1) and 1 pi of 5 U/ |xl ampliTaq gold enzyme (Applied biosystems). Thermocycler conditions 
for IL-10 or IFN-y was 3 min hot start at 95°C followed by 42 cycles of denaturation at 95°C 
for 1 min, primer annealing at 57°C for 1 min and extension at 72°C for 1 min, followed by 1 
cycle of extension at 72°C for 10 min. TGF-(3 PCR cycles also began with a hot start (2 min 
at 94°C) followed by 50 cycles of denaturation at 94°Cfor 1 min, primer annealing at 61°C 
for 1 min and extension at 72°C for 1 min, followed by 1 cycle of extension at 72°C for 10 
min. 
Analysis of RT-PCR products: Following amplification, products were separated on 1.5% 
ultrapure agarose (Gibco) in TBE buffer (Invitrogen, Carlsbald, CA), stained with ethidium 
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bromide and photographed under UV with a Gel-Doc system (Bio-Rad, Hercules, CA) 
(Figure 2). The digitized image was analyzed using an image analysis software program 
(multi-analyst version 1.0.2, Bio-Rad). The fluorescence of the target and the mimic bands 
was measured in each lane. For each point, the log of the target fluorescence area/mimic 
fluorescence area ratio was plotted against the logarithmic value for the concentration of each 
mimic added to the sample. The amount of target cytokine was calculated by determining the 
X-intercept for the point of the standard curve where the ration of target to mimic equal to 
one. 
Statistical analysis. Results were compared by using ANOVA, and significant differences 
between means were tested by Fisher protected least significant difference test using the 
Statview software package (Graphpad software, San Diego, CA). For all tests and 
comparisons only P value less than 0.05 were considered significant. 
Results and Discussion 
In the present investigation, cows with clinical Johne's disease had increased (P< 0.05) IL-10 
cytokine gene expression locally at the site of infection in all tissues tested (Figure 3A). The 
TGF-P gene expression in the ileum of the clinically infected animals was similar to 
subclinically infected animals but was significantly higher (P< 0.05) than the TGF-(3 gene 
expression in the ileum of healthy animals (Figure 3B). In other tissues, TGF-(3 gene 
expression in clinically infected cows was significantly higher (P< 0.05) than the levels of 
expression present in healthy and subclinically infected cows (Figure 3B). In contrast, cows 
with subclinical infection had significantly higher (P< 0.05) IFN-y gene expression in all 
tissues compared to clinically infected animals (Figure 3C). The IFN-y gene expression in 
healthy animal tissues was significantly lower than the levels of expression in the 
subclinically infected cows except in the ileal-cecal lymph node where levels of gene 
expression was similar for these two groups. Expression of IFN-y in tissues from healthy 
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cows was similar to the levels of expression in tissues from clinically infected animal except 
in the ileal-cecal lymph node where it was significantly higher (P< 0.05) than the IFN-y gene 
expression of the clinically infected cows. The latter results are in agreement with a previous 
study which also showed that IFN-y expression was elevated in ileal tissues and mesenteric 
lymph nodes of subclinically infected (asymptomatic) cows (Sweeney et al. 1998). 
Generally, regulatory cytokines such as TGF-(3 and IL-10 play an active role in macrophage 
deactivation and interfere in macrophage antigen-presenting ability (de Vries 1995; Lang et 
al. 2002; Tomioka et al. 2000; Tsunawaki et al. 1988). In addition, these cytokines also drive 
T cell development towards Th-2, Th-3, or T regulatory (Trl) cells, with a corresponding 
increase in antibody production and a concomitant downregulation of the Th-1 response 
(Asseman et al. 1999; Groux et al. 1997; Groux et al. 1999; Seder et al. 1998). In this study, 
the decreased IFN-y gene expression in tissues obtained from cows with clinical 
paratuberculosis infection compared to subclinically infected cows (Figure 3A) suggests a 
weakened cell-mediated immune response. Moreover, the increased expression of TGF-(3 
and IL-10 noted in clinical cows may be indicative of a mechanism causing the shift in T 
helper response from the strong Th-1 type (cell-mediated immunity) observed in subclinical 
cows towards a Th-2 type response observed in clinically infected animals. 
A previous study which reported the reduced expression of IFN-y in tissues of clinically 
infected cows also demonstrated that IL-4 gene expression in these cows was not different 
from the subclinical or healthy group (Sweeney et al. 1998). This information suggests that 
the down regulation of IFN-y gene expression was not solely a result of a shift to Th-2 type 
responses. The increased gene expression of IL-10 and TGF-(3 noted in this study instead 
suggests that cell types such as Tr-l or Th-3 cells may be involved (Groux et al. 1997; 
Othieno et al. 1999). 
Although not documented in cattle, Tr-l cells in mice and humans are anergic T cells that 
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produce high levels of IL-10, low levels of IL-2 and undetectable levels of IL-4 (Groux et al. 
1997). Another subset of anergic cells referred to as Th-3 cells were also shown to produce 
high levels of TGF-[3 and variable amounts of IL-4 and IL-10 upon activation (Chen et al. 
1994). Moreover, conditions which favor high IL-4, IL-10, or TGF-J3 production and/or low 
IFN-y production greatly enhance TGF-(3 production from Th-3 cells (Seder et al. 1998). 
Therefore, one possible mechanism involved in the downregulation of IFN-y in cows with 
clinical Johne's disease is the activation of Tr-l cells producing high amounts of IL-10 with 
the subsequent activation of TGF-(3 production by Th-3 cells. 
The role of IL-10 and TGF-(3 in the pathogenesis of other mycobacterial diseases has been 
investigated in several studies. For example, increased IL-10 levels in the sera of leprosy 
patients as well as increased IL-10 mRNA in lepromatous lesions has been observed 
(Yamamura et al. 1991). IL-10 transgenic mice had a high mycobacterial burden compared to 
wild-type mice (Murray et al. 1997) while IL-10 knockout mice showed an increased 
antimicrobial immunity and lower mycobacterial burden compared to wild-type mice 
(Murray et al. 1999). In addition, IL-10 was found to inhibit mycobacterial killing initiated 
by the presence of IFN-y in infected macrophage cell cultures (Flesch et al. 1994). 
TGF-(3 has also been demonstrated to have effects on mycobacterial infections other than M. 
paratuberculosis. Elevated expression of TGF-(3 has been noted in human patients with 
tuberculosis and incubation of macrophages with M. avium antigens, M. tuberculosis PPD, 
LAM or lipoglycan induced TGF-J3 production (Bermudez 1993; Dahl et al. 1996; Hirsch et 
al. 1994; Toossi et al. 1995). In addition, inhibition of TGF-(3 with anti-TGF-(3 antibodies 
increased the ability of M. avium-infected macrophages to kill the bacteria after stimulation 
with TNF-a and IFN-y (Bermudez 1993). This study demonstrated that IFN-y induced 
mycobactericidal activity required depletion of TGF-J3 prior to macrophage infection. 
Therefore, IL-10 and TGF-(3 appear to have powerful inhibitory activities that may abrogate 
the ability of IFN-y to induce microbicidal activity of macrophages (Hirsch et al. 1994; 
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Roach et al. 2001) in addition to their inhibitory effects on IFN-y production by T cells 
(Othieno et al. 1999). 
In conclusion, containment of infection during the subclinical phase is achieved through the 
upregulation of cell-mediated immune responses that increase the microbicidal activity of 
macrophages and is characterized by high IFN-y expression. The results of this study 
demonstrate that animals in the clinical stage of Johne's disease have decreased levels of 
IFN-y expression and an upregulation of TGF-J3 and IL-10. This suggests that the 
downregulation of IFN-y at the site of M. paratuberculosis infection in cattle may be a direct 
result of regulatory cytokines, IL-10 and TGF-(3. Taking this data together we proprosed a 
model (Figure 4) to illustrate the gene expression of IFN-y, IL-10 and TGF-(3 during Johne's 
disease progression. In chronic paratuberculosis, it is very likely that this aberrant balance of 
cytokine gene expression might contribute to the progression of M. paratuberculosis 
infection from the contained subclinical stage of disease to a more clinical state (Figure 4). 
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Table 1. Number of tissues analyzed by RT-PCR from a total of 7 healthy cows, 7 
subclinically infected cows and 9 clinically infected cows. 
Ileum IC junction IC node MLN 
Healthy 7 7 5 5 
Subclinical 6 6 6 7 
Clinical 9 9 9 9 
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Target primers 
IL-10 5 - TAC TOT TGA CCC AGT 
CTC TGC TGG -T 
TGF p 5V GGA CCT GGG CTG GAA 
GTG -3 
IFN Y 5--AATGCAAGTAGC CCA 
GAT G -3" 
Composite primers 
IL-10 5~- TAC TGT TGA CCC AGT CTC TGC TGG 
GCT GGA TGA TTG ATG CAG ACA GC -3~ 
TGF p 5 -GGA CCT GGG CTG GAA GTG GTT CTC 
CAA AATOGCTCGTGAC-3' 
IFN Y 5 - AAT GCA AGT AGC CCA GAT GGC TGG 
ATG ATT GAT GCA GAC AGC -3~ 
IL 10 5- - CAC TCA TGG CTT TGT 
AGA CAC CC -3" 
TGF p 5- CTG CTC CAC CTT GGG 
CTT -3~ 
IFN Y 5"- GAT CTG CAG ATC ATC 
CAC CGG -3" 
IL-10 5 - CAC TCA TGG CTT TGT AGA CAC CCA ATC 
TGT AGG GCT AGG CAA GTG C -3" 
TGF p 5 - CTG CTC CAC CTT GGG CTT TGG GGA 
GCT TTG AGA TTG CTG-3" 
IFN Y 5"- GAT CTG CAG ATC ATC CAC CGG TGG 
TTT ACA TAC TCT GGA GCA GGC -3~ 
Figure 1. Various target primer sequences used to amplify IL-10, IFN y, and TGF |3 cDNA 
(left) as well as their constructed mimic DNA fragment (right). Composite primer sequences 
used to compare IL-10, IFN y and TGF (3 mimic DNA fragments. Notice that the composite 
primers share the same primer sequence of the target (red part of the arrow) 
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Figure 2. Demonstration of electrophoretic separation of RT-cPCR products in 1.5% TBE 
agarose gels stained with ethidium bromide. IFN-y PGR product size is 270 bp and the mimic 
product size is 409 bp, TGF-(3 PGR product size is 223 bp and the mimic product size is 439 
bp, IL-10 PGR product is 288 bp and its mimic product size is 135 bp. Serial ten fold dilution 
of each mimic were add (left to right) along with fixed concentrations of the target cDNA (1 
|ig/|al) to each PGR reaction. Concentration for IFN-y mimic starts at 1 pg/|il, TGF-[3 starts at 
50 pg/(.il and for IL-10 starts at 0.05 pg/gl. 
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Figure 3. Expression of cytokine-specific gene in tissues recovered from healthy or M. 
paratuberculosis infected cattle. Cytokine concentrations from the total target cDNA added 
in each reaction. Following quantitation of PGR products, log target fluorescence /mimic 
fluorescence ratio was calculated and plotted against the log mimic concentration. The 
intercept X represents the target concentration for each cytokine (A) IFN-y, (B) IL-10, (C) 
TGF-p (different letters represent a statistical difference (P< 0.05) when comparing 
production of each cytokine within a given tissue). The number of tissues analyzed is 
represented in table 1. 
76 
c 
o TGF P 
C 
<D O 
C 
O 
o 
IL-10 
IFN y 
Disease progression 
Subclinical Clinical 
Figure 4. The hypothetical expression of IL-10, IFN y and TGF (3 at the site of infection (i.< 
ileum) during progression of M. paratuberculosis infection from asymptomatic subclinical 
state to full-blown clinical disease. 
77 
CHAPTER THREE. EFFECTS OF IFN-y, IL-10 AND TGF-|3 ON 
SURVIVAL OF MYCOBACTERIUM PARATUBERCULOSIS IN 
PERIPHERAL BLOOD MONONUCLEAR CELL CULTURES 
A paper prepared for submission to Infection and Immunity 
MOHAMMAD S. KHALIFEH AND JUDITH R. STABEL 
Abstract 
The presence of IFN-y is critical in containing Mycobacterium paratuberculosis infection. 
However, the contribution of other immunoregulatory cytokines such as IL-10 and TGF-(3 in 
Johne's disease is not investigated yet. In this study we examined the effects of in vivo and in 
vitro infection with M. paratuberculosis on the production of IFN-y, IL-10 and TGF-(3 by 
peripheral blood mononuclear cells (PBMC). We also examined the effects of IFN-y, IL-10 
and TGF-(3 on M. paratuberculosis survival in the cell cultures. PBMC obtained from 
naturally infected cows, regardless of their disease status, specifically upregulated IL-10 and 
TGF-(3 in culture supernatants in response to stimulation with live M. paratuberculosis. Non-
stimulated PBMC recovered from subclinically infected animals secreted the lowest levels of 
TGF-(3 but after stimulation with live M. paratuberculosis, TGF-(3 levels in the culture 
supernatant increased to levels similar to that produced by PBMC from healthy animals. 
Compared to healthy cows, naturally infected animals had higher numbers of viable M. 
paratuberculosis recovered from their culture after in vitro infection with M. 
paratuberculosis. The addition of exogenous IL-10 and TGF-(3 to PBMC recovered from 
healthy cows inhibited the bactericidal activity of these cells as evidenced by the increased 
number of viable M. paratuberculosis present in the culture compared to cell cultures 
containing medium alone. These data suggest an important immune regulatory role of IL-10 
and TGF-(3 during infection with M. paratuberculosis which may be directly related to their 
effects on macrophage activation and killing of M. paratuberculosis. 
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Introduction 
Johne's disease typically progresses through three distinct stages (2). The division of these 
stages depends upon the existence of clinical signs and the correlation of these signs with the 
fecal shedding of M. paratuberculosis. Accordingly, the first and the second stages are 
considered subclinical stages where animals are asymptomatic. Animals may remain in these 
stages without developing clinical disease or might progress to the clinical stage after 3-4 
years of infection. During the first subclinical stage, the infection persists without the ability 
to detect shedding of M. paratuberculosis in the feces followed by the subclinical 
intermittent excretory phase. The third or the clinical excretory stage is characterized by 
progressive symptoms associated with persistent shedding of high numbers of bacteria in the 
feces and severe diarrhea with concomitant weight loss. The stages of Johne's disease reflect 
an ongoing struggle within the host animal's immune system. Animals in the excretory 
subclinical stage are reported to have increased IFN-y expression locally at the site of 
infection (19) as well as higher IFN-y production in culture supematants after stimulation of 
peripheral blood mononuclear cell culture with M. paratuberculosis antigens (18). As M. 
paratuberculosis-infected animals progress to a more clinical state, local and peripheral IFN-
y production declines (16, 18, 19). 
Following ingestion of M. paratuberculosis by the neonatal calf, the bacteria cross M cells 
lining the Peyer's patches and can be then engulfed by resident macrophages in the distal 
ileum where the bacteria can survive and replicate (11). It has been suggested that the host's 
immune system responds to M. paratuberculosis infection by recruiting more macrophages 
and lymphocytes to the site as well as by activation of immune cells such as yô T cells, CD4" 
T cells, and cytolytic CD8+ T cells (4, 10). These cells could operate directly on the infected 
macrophages through cell to cell contact or/and indirectly through production of cytokines 
such as IFN-y, TNF-a, and IL-6 which cause macrophage activation and further activation of 
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T cells (10). Therefore, it is important for macrophages to remain in contact with the proper 
immune cells and their products to overcome this type of infection. 
It has been hypothesized that during the interaction between host immunity and M. 
paratuberculosis, a deviation from the proper immune response arises and disrupts the ability 
of the host to contain the disease. Although a mechanism has not been identified, the 
decrease in IFN-y noted during the clinical stage signals a disruption in the effector phase of 
host immunity. Exogenous IFN-y has been shown to stimulate monocytes to kill M. 
paratuberculosis (23). In other mycobacterial diseases, such as tuberculosis, a similar 
upregulation of IFN-y production during the contained stage of the disease has been reported 
(8, 15). With regards to macrophage activation, addition of recombinant human IFN-y to 
monocyte cell cultures enhanced the ability of these cells to limit growth of M. tuberculosis 
and M. bovis (8, 15). Conversely, infection of IFN-y knockout mice with a sublethal dose of 
M. bovis or M. tuberculosis resulted in increased mortality and increased bacterial numbers 
recovered from spleen, liver, and lung (3,6). 
When M. tuberculosis infection progresses into an advanced stage (disseminated 
tuberculosis) a decrease in IFN-y production occurs and a new profile of cytokines dominated 
by the anti-inflammatory cytokines TGF-P and IL-10 emerges. Following mycobacterial 
infection, evidence obtained from studies with IL-10 transgenic mice and IL-10 knockout 
mice indicates that IL-10 is often associated with immune suppression in and with the 
increased replication of mycobacteria (12, 13). TGF-(3 has also been shown experimentally to 
enhance the intracellular growth of M. tuberculosis in human monocytes (9). After infection 
of monocytes with M. tuberculosis, production of TGF-P in cell culture supematants was low 
in the first 24 hrs of incubation (<50 pg/ml) then increased up to 8-fold after 4 days in culture 
(9). This increased production of TGF-P was accompanied by decreased ability of monocytes 
in culture to control growth of M. tuberculosis. 
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Recently, we reported that the immunomodulatory cytokines, TGF-(3 and IL-10, were 
upregulated in the tissues of cows with clinical Johne's disease (manuscript in preparation). 
The presence of these anti-inflammatory cytokines that modulate the effects of pro­
inflammatory cytokines such as IFN-y might be one mechanism that enhances the survival of 
mycobacteria within the host. In the present study, we investigated the effects of in vitro 
infection with M. paratuberculosis on the production of IFN-y, IL-10, and TGF-P production 
by PBMC isolated from healthy and naturally infected cows. We also investigated the effects 
of exogenous IFN-y, IL-10, and TGF-P stimulation on the ability of monocyte-derived 
macrophages in unfractionated cell cultures to kill M. paratuberculosis. These studies 
indicate that 11-10 and TGF-P downregulate the bactericidal activity of monocyte-derived 
macrophages. 
Materials and Methods 
Animals. The animals used in this experiment were placed in three groups consisting of five 
non-infected healthy cows, four cows naturally infected with M. paratuberculosis but 
asymptomatic (i.e., subclinical), and five cows with the clinical form of Johne's disease. 
Infection was monitored bacteriologically for the fecal shedding of M. paratuberculosis 
using standard culture methods previously described (17). By definition, clinical animals 
were shedding more than 100 colony forming units (CFU) per gram of feces and presented 
with weight loss and intermittent diarrhea. Subclinically infected cows were shedding less 
than 10 CFU/g of feces. All animals were housed in American Association for Accreditation 
of Laboratory Animal Care-accredited facilities and all animal related procedures were 
approved by the IACUC (National Animal Disease Center, Ames, Iowa). 
Blood collection, culturing conditions and sample collection. Blood was collected from 
the jugular vein in 2X acid-citrate-dextrose (ACD) (1:10). Peripheral blood mononuclear 
cells (PBMC) were isolated from the buffy-coat fractions of the peripheral blood as 
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previously described (1). PBMC were resuspended in RPMI-1640 (Gibco, Grand Island, NY) 
containing 10% PCS (Atlanta Biologies, Atlanta, GA), 100 units/ml penicillin G sodium 
(Gibco) 100 |ig/ml streptomycin sulfate (Gibco), 0.25 jig/ml amphotericin B (Gibco), and 2 
mM L-glutamine (Gibco). Cells were cultured at 2 X 106/ ml in 24-well flat-bottomed plates 
(Nunc, Life Technologies) for 6 days at 39°C in 5% C02 in a humidified atmosphere to allow 
monocytes in the unfractionated PBMC cultures to develop into macrophages. The plates 
were then centrifuged at 400 x g for 2 min and the supematants were removed without 
disturbing the cells in culture. Cells in duplicate wells were cultured with fresh medium 
containing 100 ng/ml human IL-10 (200-10, Peprotech, Rocky Hill, N.J.), 100 ng/ml bovine 
IFN-y (generously donated by Novartis Animal Health, Basel, Switzerland), 10 ng/ml human 
TGF (3 (100-21R, Peprotech), 100 ng/ml IL-10 plus 10 ng/ml TGF-P or left without cytokine 
stimulation. Cultured cells were incubated overnight (18 hrs) then infected the next day with 
M. paratuberculosis, strain 19698 (NADC, Ames, IA) at a ratio of 10 bacteria per one 
adherent PBMC (24). Replicate wells of the in vitro infected and non-infected cell cultures 
were also concurrently treated with 1 |ig/ml of LPS (Escherichia coli 011:B4-W; Sigma) as 
a non-specific stimulator of macrophages in the study. To assess cytokine production, cell 
culture supematants were collected at 8 hrs, 3 days, or 6 days after in vitro infection and 
stored at -20°C prior to cytokine measurement. For cultures that had been infected with M. 
paratuberculosis, cells that were left in each well after the collection of culture supernatant 
were lysed and washed several times with distilled H20, left overnight at room temperature 
(RT) and cultured on Herrold's egg yolk medium (HEYM). 
Bacteria. M. paratuberculosis strain 19698 (NADC) was grown in Middle-brook 7H9 broth 
(pH 6.0) supplemented with oleic acid albumin dextrose complex (OADC, Becton Dickinson 
Microbiology). The bacteria were harvested, washed three times with phosphate-buffered 
saline (PBS pH 7.4; 0.15M), resuspended in PBS to a final concentration of 109/ml as 
determined by the absorbance at 540 nm. Bacterial stocks were then frozen in PBS at - 80°C 
until used in the experiments. Prior to in vitro infection, frozen bacterial stocks were thawed 
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and clumps were dispersed by brief sonication at 25 W for 40 sec with a Tekmar sonic 
disturber (Lorton, VA). The frozen bacterial stocks were monitored for viable counts by 
culturing on HEYM. Viable counts in stocks were reduced after thawing and sonication to 
approximately 1 X 108 CFU/ml. 
Assessment of cell phenotypes in the unfractionated PBMC before cytokine treatments 
as well as prior to in vitro stimulation with live M. paratuberculosis. To assess the cell 
phenotypes present in the unfractionated PBMC, flow cytometric analysis of the cultured, 
unfractionated PBMC was performed after 6 and 7 days in culture. Cells at each time point 
were stained with monoclonal antibodies (mAb) for different cell surface molecules. A single 
color flow cytometric analysis of T cells for the expression of CD4 (CACT138A), CD8a 
(CACT80A), or yô TCR-N24 (GB21A) (VMRD, Pullman, WA) was performed. Briefly, 50 
|xl of anti-CD4, CD8, or yô cell surface markers were incubated for 15 min in room 
temperature (RT) with 100 (il of 2 X 106 cells/ml at the working concentration of 7, 10, or 7 
jig/ml, respectively. Cells were then washed once by centrifugation at 400 x g for 2 min. 
Bound markers were visualized by incubating cells for 15 min with 50 |il of phycoerythrin-
(PE) conjugated goat anti-mouse IgGl (1:1000) (Southern Biotechnology Associates, Inc., 
Birmingham, AL) for the mouse anti-bovine CD4 marker, anti-IgG2b (1:1000) for the mouse 
anti-bovine yô marker, and anti-IgM (1:2000) for the mouse anti-bovine CD8 marker 
(Southern Biotechnology Associates, Inc., Birmingham, Ala). Cells were then washed and 
incubated for 5 min with DAPI (4',6-diamidino-2-phenylindole) (Sigma, St. Louis, Mo) to 
gate out the dead cells then washed and resuspended in FACS buffer (PBS, 1% FCS and 0.1 
% sodium azide). 
For analysis of B cells and MHC II bearing cells, a two-color flow cytometric analysis was 
performed. Briefly, 100 jxl of cell cultures at 2 X 106 cells/ml were incubated for 15 min at 
RT with 50 jo.1 of B cell marker BAQ155A (7 |ig/ml) (VMRD) and 50 |0,1 of MHC II marker 
CH34A (3.5 |ig/ml) (VMRD). Cell surface markers were then visualized by incubating cells 
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for 15 min with 50 (il of goat anti-mouse immunoglobulin IgG2a PE conjugated (1:500) to 
detect bound anti-bovine MHC II marker and 50 |il of goat anti-mouse immunoglobulin IgGl 
(FITC) conjugated (1:250) to detect the bound anti-bovine B cell marker. Cells were then 
washed and resuspended in FACS buffer. To gate out the dead cells from the flow analysis, 
cells were incubated with DAPI at 1:1000 (10 mg/ml) (Sigma, St. Louis, MO) before the 
final wash. 
Data from 5000 events per sample were acquired (Cell quest software; BD Biosciences, San 
Jose, CA) using flow cytometry (BD LSR, BD Biosciences). For all analyses, only 
mononuclear cells that were DAPI negative were gated and analyzed for phenotypic marker 
expression by Flowjo software (Tree Star Inc, San Carlos, CA). 
Assessment of M. paratuberculosis survival in the extended un fractionated PBMC 
cultures. The number of viable M. paratuberculosis in each cell culture lysate and its 
corresponding cell culture supernatant from each treatment were separately cultured on 
HEYM medium. Growth was measured by counting the CFU following serial 10-fold 
dilutions on duplicate HEYM slants for each treated well. HEYM slants were incubated at 
39°C for 12 weeks. CFU recovered from the cell culture lysates were added to the number of 
CFU recovered from the corresponding cell culture supematants and represented the 
surviving M. paratuberculosis after each treatment. The number of CFU from the cell culture 
supematants alone represented M. paratuberculosis that was either not phagocytized 
originally or was phagocytized and released by macrophages after cell death. 
Measurement of IFN-y, IL-10, and TGF-P production in cell culture supernatant by 
ELISA. IFN-y was measured using Bovigam bovine IFN-y test kit (CSL Veterinary, 
Parkville, Victoria, Australia) as described by the manufacturer. For the detection of bovine 
IL-10, purified rat anti-human IL-10 capture mAb (JES3-19F1) (PharMingen, San Diego, 
CA) and biotinylated rat anti-human IL-10 detection mAb (JES3-12G8) (PharMingen) were 
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used. MaxiSorp microtiter plates (NUNC, Rochester, NY) were coated with the capture mAb 
(100 pil per well at 2 ng/ml) overnight at 4°C. Plates were then blocked with 1 % gelatin in 
PBS for 2 hrs at RT. Plates were then washed 4 times with 1% Tween 80 in PBS washing 
buffer. The diluted samples (1: 1.5 in RPMI) and serial 2-fold dilutions of rhIL-10 standard 
(starting at 20 ng/ml) were added in duplicate and incubated overnight at 4°C. Plates were 
then washed 5 times with washing buffer before incubating with the detection biotinylated 
anti-human IL-10 mAb (100 pi at 1 |ig/ml) for 1 hour at RT. Plates were washed 5 times 
with washing buffer and 100 |il of avidin - horseradish peroxidase (HRP) conjugate (1:2000) 
(PharMingen) was added to each well and incubated for 30 min at RT. Following another 
wash cycle, wells were incubated with substrate solution (40 mM ABTS (2,2' -azino-di-
ethylbenzthiozoline-6-sulfonic acid) in citrate buffer, pH 4.0) and color development 
quantified after 10 min by measuring absorbance at 405 nm with a Wallac Victor 1420 multi-
label counter ELISA plate reader (PerkinElmer, Gaithersburg, MD). 
TGF-P was detected by coating MaxiSorp microtiter plates (NUNC) with 100 pi of anti-
human TGF-p capture mAb (MAB240) (R&D system, Minneapolis, MN) at 2 jig/ml and 
then using biotinylated rat anti-human TGF-P mAb (BAF240) (R&D system) at 100 ng/ml as 
the detection mAb. The plates with the capture mAb were incubated overnight at RT then 
washed 4 times with 0.5% Tween 20 in PBS and blocked with 5% Tween 20, 5% sucrose 
and 0.05% NaN3 in PBS (i.e., blocking buffer) for 2 hrs at RT. Diluted samples (1 : 6) or the 
rhTGF P standards (5 ng/ml to 0.078 ng/ml diluted in RPMI) (Peprotech) were acidified to 
pH 2.0 with 1 N HCL for 10 min at RT to activate the latent TGF-P then samples were 
neutralized to pH 7.2 - 7.6 by 1.2 N NaOH/ 0.5 M HEPES. Activated samples were then 
added to plates coated with the TGF-p capture mAb within 5 min and incubated for 2 hrs at 
RT. Plates were then washed 4 times with washing buffer followed by incubation with TGF-
P detection mAb for 2 hrs at RT. Plates were then washed 4 times and incubated with 100 |il 
of strepavidin - HRP (1:2000) (PharMingen) followed by ABTS substrate solution addition 
as described above for the IL-10 ELISA. The concentration of cytokines for each of the 
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assays was estimated from the standard curve generated using recombinant bovine IFN-y 
(Novartis Animal Health), rhIL-10 (PharMingen), and rhTGF-|3 (Peprotech). 
Statistical analysis. Results were compared by using 2 way ANOVA, and significant 
differences among means were tested by Fisher protected least significant difference test 
using the Statview software package (Graphpad software, San Diego, C A). For all tests and 
comparisons only P values less than 0.05 were considered significant. 
Results 
Mononuclear cell profile in unfractionated cell culture. After six days in culture, most of 
the adherent cells in culture assessed by light microscopy were stellate in shape, consistent 
with typical macrophage morphology (Figure 1). This suggested the generation of monoctye-
derived macrophages in the extended unfractionated PBMC culture. Flow cytometric analysis 
of the cellular phenotypes in the unfractionated PBMC cultures were noted to be different 
between animal groups (Table 1 & 2). The subclinically infected cows had more (P< 0.05) yô 
T cells in their unfractionated cell cultures than healthy and clinically infected cows after 7 
days in culture. MHC IP B cells+ and MHC II B cells+ were higher (P< 0.05) in the clinical 
group compared to healthy or subclinically infected group after 6 days in culture and on day 7 
after the addition of cytokines in the fresh complete medium (Table 1 & 2). 
Effect of infectious status of cows and in vitro infection of PBMC cultures on IFN-y IL-
10, TGF-P. Effects of animal infection status (i.e., healthy, subclinical or clinical) and in vitro 
infection with M. paratuberculosis on the secretion of IFN-y, IL-10, or TGF-(3 by PBMC is 
presented in Tables 3, 4, and 5, respectively. In non-infected cell cultures isolated from 
clinical cows, IFN-y production significantly (P< 0.05) decreased with time (Table 3). 
Infected animals (subclinical or clinical) had significantly higher (P< 0.05) IFN-y production 
in non-infected culture supematants compared to healthy non-infected controls. In contrast, 
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after in vitro infection with M. paratuberculosis, IFN-y production remained fairly constant at 
all time points in PBMC cultures of subclinically and clinically infected cows. In PBMC 
cultures of healthy animals, the in vitro infection resulted in a continuous accumulation of 
IFN-y production with time (P< 0.05). 
The in vitro production of IL-10 by PBMC from clinically infected and healthy animals 
decreased (P< 0.05) with time (8 vs 6 days) while it remained fairly constant in cell cultures 
of the subclinically infected animals at all time points tested in this experiment (Table 4). 
After in vitro infection with live M. paratuberculosis, there was an upregulation (P < 0.05) of 
IL-10 production in the cultures containing cells recovered from naturally infected animals 
but not in cultures containing cells isolated from the healthy animals (Table 4). 
The level of TGF-P production increased (P< 0.05) with time (8 hrs vs. 6 days) in cell cultures 
obtained from healthy cows in the absence of M. paratuberculosis (Table 5). Compared to 
healthy and clinical animals at day 6, TGF-P levels were significantly (P< 0.05) lower in non-
infected cell culture supematants of cows in the subclinical stage of the disease. Following the 
in vitro infection with M. paratuberculosis, there was a resultant upregulation (P< 0.05) of 
TGF-P production for both subclinical and clinical cows (Table 5), with levels of TGF-P 
produced by clinical cows becoming similar to levels produced by healthy cows in non-
infected cultures. 
The effect of LPS on TGF-P, IL-10 and IFN-y. Cells in the unfractionated PBMC cultures 
were inherently able to produce IFN-y when non-specifically stimulated with LPS (Figure 2). 
While the addition of M. paratuberculosis to cell culture caused an upregulation of TGF-p 
and IL-10 in the naturally infected animals, addition of LPS as a non-specific stimulator of 
monocyte-derived macrophages in culture did not affect TGF-P (Figure 2C) or IL-10 (Figure 
2B) production but resulted in a significant (P< 0.05) boost in IFN-y production in cell 
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cultures from all animal groups (Figure 2A). The effect of co-stimulation with LPS and live 
M. paratuberculosis on cytokine production was not additive (data not shown). 
Effects of exogenous cytokines on M. paratuberculosis survival. Regardless of disease 
status, PBMC from naturally infected animals had decreased (P< 0.05) capacity to kill M. 
paratuberculosis in vitro by day 6 (Figure 3). There was no significant difference between the 
number of CFU recovered from subclinical animals and clinical animals (data not shown). 
Pretreatment with exogenous IL-10 or TGF-(3 or a combination of both for 18 hrs before 
infection of cultured PBMC isolated from healthy animals with live M. paratuberculosis 
resulted in higher (P< 0.05) numbers of CFU recovered when compared to medium control 
cultures (no added cytokines) control cultures 6 days after in vitro infection (Figure 4). 
Pretreatment with IFN-y had no significant effect on the number of viable M. paratuberculosis 
recovered from cell culture (Figure 4) although a trend for decreased number of recovered 
bacteria was observed. 
Interaction of exogenous cytokines and infection on IFN-y, IL-10 and TGF-P 
production. Pretreatment of PBMC with exogenous TGF-P significantly increased (P< 0.05) 
endogenous IL-10 production in all groups (Figure 5). This effect was noted regardless of 
period of incubation, LPS stimulation or in vitro infection with live M. paratuberculosis. 
Addition of exogenous IL-10 and TGF-P to PBMC cultures had significant (P< 0.05) 
downregulatory effects on IFN-y production (Figure 6). Production of IFN-y was significantly 
(P< 0.05) reduced by the addition of TGF-P alone of in combination with IL-10 to PBMC 
regardless of animal group (Figure 6A). In vitro infection with M. paratuberculosis resulted in 
an overall increase in IFN-y production compared to noninfected PBMC cultures regardless of 
cytokine treatment or animal groups Figure 6B). Similar to noninfected cell cultures, the 
addition of anti-inflammatory cytokines, 11-10 and TGF-P, to infected cell culture resulted in a 
significant (P< 0.05) abrogation of IFN-y production. The inhibitory effects of these anti­
inflammatory cytokines on IFN-y production was most noticeable (P< 0.05) in cell cultures 
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obtained from subclinically infected animals, whereas, cells isolated from clinically infected 
cows were the least (P< 0.05) affected (Figure 6). 
Discussion 
Previous studies have reported significant effects of IFN-y, on the ability of monocytes to kill 
mycobacteria, including M. paratuberculosis (8, 15, 23). In the present study, we evaluated 
the effect of IFN y, IL-10 or TGF-(3, on the survival of M. paratuberculosis in monocyte-
derived macrophages present in unfractionated PBMC cultures recovered from cows 
naturally infected with M. paratuberculosis as well as healthy animals. Relative to non­
infected cultures, in vitro challenge of cell cultures with live M. paratuberculosis resulted in 
enhanced production of IFN-y in cell cultures derived from clinically infected and healthy 
animals but not in cultures derived from the subclinically infected group. These data differ 
from what was previously reported for IFN-y production where the amounts of IFN-y after 
stimulation with either M. paratuberculosis whole cell sonicate or live M. paratuberculosis 
was higher in PBMC cultures from subclinically infected cows compared to cultures from 
healthy or clinical cows (16, 18). However, the culture conditions in the current study were 
quite different as we used an extended (i.e., 7-12 days) cell culture system and previous 
studies utilized freshly isolated PBMC. 
The difference in IFN-y production might indicate that after development of monocytes into 
macrophages, antigen presentation as well as cytokine production from cultured 
macrophages and lymphocytes favors a Th-1 response as represented by increased IFN-y 
production. Before in vitro infection with M. paratuberculosis, IFN-y production remained 
low in the supematants obtained from PBMC culture of healthy animals. In the subclinically 
infected animals production of IFN-y remained consistent across time while in cell cultures 
obtained from clinically infected cows, it decreased with time. However, the production of 
IFN-y across time in culture on average was higher in the supernatant of cells from naturally 
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infected animals than healthy animals. After infection with M. paratuberculosis the 
production of IFN-y in PBMC cultures from healthy animals increased with time while in 
subclinically infected animals the amount of IFN-y produced did not change over time. In 
cell cultures derived from clinically infected animals, IFN-y was upregulated and remained 
constant across time. These changes may imply that the control mechanism(s) for IFN-y 
production are different in the three groups and it seemed that PBMC from clinically infected 
animals were generating some type of downregulatory mechanism that led to decreased IFN-
y production over time. However, in the presence of a stimulus like LPS, IFN-y production 
was enhanced. In subclinically infected animals, the low TGF-(3 presence in cell culture 
before in vitro infection with M. paratuberculosis correlate with the consistent and high 
production of IFN-y in these animals. Nevertheless, after in vitro infection, IL-10 amounts 
increased and possibly resulted in the inhibition of further IFN-y production. In the clinically 
infected animals, the regulation of IFN-y production might involve different factors such as 
cells survival and phenotypes present. 
The differences between cultured cells from subclinically and clinically infected animals 
included a higher percentage of yô T cells in cultures of subclinical animals while higher 
percentage of B cells and MHC II B cell in cultures of clinically infected animals were 
noted. The higher percentage of these cells may have affected the cytokine production in this 
study. Therefore, it might be informative to investigate the role of these cells in the 
pathogenesis of M. paratuberculosis infection and whether these cells are the source of the 
inhibitory cytokines, IL-10 and TGF-(3. 
In this study, extended culture of unfractionated PBMC specifically upregulated IL-10 and 
TGF-p production after stimulation with live M. paratuberculosis but not in response to non­
specific stimulation with LPS. Interestingly, the ability of M. paratuberculosis to upregulate 
IL-10 and TGF-P was noted in animals naturally infected with M. paratuberculosis 
regardless of the disease state but not from cells recovered from healthy animals. Therefore, 
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in the absence of IL-10 and TGF-(3 upregulation, cells from all groups regardless of their 
infection status were capable to produce IFN-y (e.g., LPS stimulation). This is also 
demonstrated after the addition of exogenous cytokines to the unfractionated PBMC culture. 
The interaction of TGF-P, IL-10, and IFN-y confirmed that the anti-inflammatory cytokines 
(i.e., TGF-(3 and IL-10) downregulate IFN-y production in cell culture and that TGF-p 
potentiated IL-10 production. Similarly, TGF-P has been shown to upregulate IL-10 
production in M. tuberculosis infected cell cultures (14). TGF-P and IL-10 were found to 
synergistically down-regulate IFN-y production by T cell stimulated with M. tuberculosis 
PPD (14). 
This is the first published observation to report significant effects of M. paratuberculosis 
infection on the production of the regulatory cytokine, TGF-P and 11-10. Results noted in the 
present study are similar to results documented for other mycobacterial diseases such as 
tuberculosis (9, 21). Tuberculosis patients with advanced disease (i.e., disseminated 
tuberculosis) had high TGF-p as well as IL-10 production compared to patients in the early 
stage (contained tuberculosis) of infection (7, 14, 20). In addition, mycobacteria in vitro 
infection of cell cultures from tuberculosis patients further increased TGF-P and IL-10 
production (14). Regarding IL-10, one study recently reported higher IL-10 gene expression 
in PBMC isolated from cows with clinical paratuberculosis compared to cells from healthy 
animals (5). In addition, upregulation of IL-10 gene expression was also noted in monocyte-
derived macrophages obtained from healthy animals after stimulation with live M. 
paratuberculosis (22). 
The decreased bactericidal activity of PBMC recovered from naturally infected animals 
correlated with the increased production of TGF-P and IL-10 in these cell cultures. In support 
to this observation, it was determined that the addition of these cytokines to cell cultures of 
healthy animals also increased the number of surviving M. paratuberculosis recovered 
compared to control cell cultures. These results are in agreement with previous reports on the 
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effects of TGF-P and IL-10 on the survival of M. tuberculosis. For example, incubation of 
monocyte cell cultures from healthy individuals with 10 ng/ml of rTGF-P prior to infection 
with M. tuberculosis resulted in 3-fold increase in the number of CFU recovered from cell 
culture lysates (9). A singular effect of IL-10 on mycobacterial survival was also 
demonstrated in a study in which intravenous inoculation of IL-10 transgenic mice with 
Calmette-Guerin bacillus (BCG) resulted in dissemination of the bacteria throughout the 
body for the course of the study (12 weeks) (12) 
Addition of exogenous IFN-y to monocyte-derived macrophages in the unfractionated PBMC 
culture did not decrease the number of viable bacteria recovered from cell culture after in 
vitro infection. This is different from what was previously reported where monocyte cell 
culture stimulated with IFN-y resulted in decreased M. paratuberculosis viability (23). 
Therefore, it might be that under our culture conditions, stimulation of the monocyte-derived 
macrophages in the presence of T cells in the unfractionated cell culture left macrophages 
refractory to further IFN-y stimulation probably through the production of inhibitory 
cytokines such as IL-10 and TGF-p. 
In summary, IL-10 and TGF-p had inhibitory roles on the destruction of intracellular M. 
paratuberculosis, perhaps through their effects on IFN-y production. Therefore, upregulation 
of IL-10 and TGF-P even in the presence of high IFN-y production (e.g., cells from naturally 
infected cows) likely resulted in less effective killing of the M. paratuberculosis in these 
animals compared to healthy animals which. Taken together, data from this study supports a 
model in which the progression of Johne's disease from a subclinical stage to a more clinical 
stage is the result of an imbalance of cytokine production favoring TGF-P and IL-10 over 
IFN-y production. This imbalance might be due to the difference in the type of specific cells 
activated at each disease stage. 
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Table. 1. Phenotypic analysis of bovine PBMC after 6 days in culture. 
Cell types* Healthy Subclinical Clinical 
yô T cells 16.28 ± 1.07+ 16.85 ±5.35 14.90 ±0.3 
CD4+cells 28.15 ±2.96 36.85 ± 3.35 24.95 ±6.15 
CD 8 a+ cells 23.60 ± 2.5 22.00 ±1.10 18.95 ±0.15 
MHCirBceir 17.55
a ± 3.15 10.13" ±4.38 31.60" ±6.30 
MHC II Bceir 7.54 ± 2.46 5.73 ± 1.74 7.10 ± 1.79 
MHC II+B cell- 3.34'±0.76 4.11
a ± 0.15 15.35" ±0.55 
Different letters in rows represent a statistically significant difference (P< 0.05) 
* cells were analyzed by flow cytometry as described in material and methods, 5000 cells 
were analyzed for each sample. 
t results are expressed as the mean ± SEM for 4 healthy animals, 2 subclinically infected, 
and 2 clinically infected animals. 
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Table. 2. Phenotypic analysis of bovine PBMC after 7 days' in culture. 
Cell types' Healthy Subclinical Clinical 
yô T cells 20.09" ±6.81 27.25' ± 0.25 14.80" ± 1.00 
CD4+ cells 28.23 ±2.71 33.70 ±9.70 18.00 ±6.30 
CD 8 a+cells 24.63 ± 0.84 19.65 ±4.85 10.72 ±7.18 
MHCII+Bceir 14.38'±2.22 14.82'±4.98 36.45 "± 1.95 
MHCIIBceir 17.88 ±5.18 7.51 ± 1.05 9.39 ±4.91 
MHC II+B cell- 4.82'±2.12 5.05'±3.06 15.30
b ± 3.00 
Different letters in rows represent a statistical significance (P< 0.05) 
Ï 18 hours after the replacement of the supernatant in culture with fresh medium and before 
the addition of M. paratuberculosis to the in vitro cultures. 
* cells were analyzed by flow cytometry as described in Material and Methods, 5000 cells 
were analyzed for each sample. 
t results are expressed as the mean ± SEM for 4 healthy animals, 2 subclinically infected, 
and 2 clinically infected animals. 
Table 3. IFN-y production in cell culture supematants x from non-infected healthy cows and cows with subclinical or clinical 
Johne's disease. 
M. paratuberculosis infection 8 hours 3 days 6 days Average 
Healthy Y No 0.40*
1 ± 0.17 0.06* ± 0.04 0.89f ± 0.49 0.45» ±0.19 
Yes 
0.92* ± 0.38 4.85* ± 2.00 8.73f ± 2.74 4.83e ± 1.40 
Subclinical Y No 3.20* ± 1.03 1.44* ± 0.87 2.36* ±1.66 2.33
bd ± 0.68 
Yes 2.96* ± 0.26 3.36* ± 0.88 4.05* ± 2.00 3.45
bc ± 0.68 
ClinicalY No 2.91* ± 0.32 1.16
f ± 0.34 0.72f ± 0.45 1.60d ± 0.32 
Yes 
5.26* ± 0.73 6.79* ± 1.49 4.84* ± 1.73 5.63e ± 0.77 
Different letters in columns represent a statistically significant difference (P< 0.05) 
Different symbols in rows represent statistically significant difference (P< 0.05) 
X PBMC culture medium was replaced with complete medium on day 6. After 18 hours (day 7), cells in culture were stimulated 
with live M. paratuberculosis at 10:1 bacteria to adherent cell ratio. Culture supematants were collected at 8 hours, 3 days, and 6 
days after in vitro infection and analyzed by ELISA. The average represents the concentration ± SEM of IFN-y produced (ng/ml) 
at all time points in the media control supematants with or without in vitro infection with M. paratuberculosis. 
Y Number of animals in each group was five healthy cows, four subclinically infected cows and five clinically infected cows 
Table 4. IL-10 production in cell culture supematants x from non-infected healthy cows and cows with subclinical or clinical 
Johne's disease. 
M. paratuberculosis infection 8 hours 3 days 6 days Average 
Healthy Y No 4.72* ± 0.76 3.24*
f ± 0.78 2.28t ± 0.22 3.41a ± 0.45 
Yes 
6.38* ±1.5 5.00* ± 1.63 3.79* ±0.61 5.06ac ± 0.79 
Subclinical Y No 4.59* ± 1.09 5.37* ± 0.92 3.30* ± 0.79 4.42= ± 0.55 
Yes 
13.76* ±4.31 5.54* ± 0.50 8.18* ±2.51 9.16b± 1.83 
Clinical Y No 7.44* ± 2.067 4.33
n ± 0.75 2.51f ± 0.44 4.76* ± 0.88 
Yes 10.51* ± 2.01 10.33* ±3.14 4.6* ± 1.23 8.48
bc± 1.42 
Different letters in columns represent a statistically significant difference (P< 0.05) 
Different symbols in rows represent statistically significant difference (P< 0.05) 
X PBMC culture medium was replaced with complete medium on day 6. After 18 hours (day 7), cells in culture were stimulated 
with live M. paratuberculosis at 10:1 bacteria to adherent cell ratio. Culture supematants were collected at 8 hours, 3 days, and 6 
days after in vitro infection and analyzed by sandwich ELIS A using anti-human IL-10 monoclonal antibodies. The average 
represents the concentration ± SEM of IL-10 produced (ng/ml) at all time points in the media control supematants with or without 
in vitro infection with M. paratuberculosis 
Y Number of animals in each group was five healthy cows, four subclinically infected cows and five clinically infected cows 
Table 5. TGF-(3 production in cell culture supematantsx from non-infected healthy cows and cows with subclinical or clinical 
Johne's disease. 
M. paratuberculosis infection 8 hours 3 days 6 days Average 
Healthy No 7.18* ± 1.124 
9.97*+ ± 2.2 14.51+±3.10 11.42» ±1.74 
Yes 11.82* ± 2.12 13.79* ± 3.02 15.41* ±2.51 13.68=" ±1.48 
Subclinical No 6.77* ± 0.58 7.27* ± 1.64 7.64* ± 1.40 7.22
b ± 0.68 
Yes 10.39* ± 0.53 13.78+± 1.24 12.3*+± 1.22 12.15» ± 0.69 
Clinical No 8.90* ± 1.16 11.62* ± 1.63 12.86* ± 1.66 11.13» ±0.92 
Yes 14.57* ± 3.01 16.09* ± 2.54 21.41* ± 1.63 17.35'±1.53 
Different letters in columns represent a statistically significant difference (P< 0.05) 
Different symbols in rows represent statistically significant difference (P< 0.05) 
X PBMC culture medium was replaced with complete medium on day 6. After 18 hours (day 7), cells in culture were stimulated 
with live M. paratuberculosis at 10:1 bacteria to adherent cell ratio. Culture supematants were collected at 8 hours, 3 days, and 6 
days after in vitro infection and analyzed by ELIS A. The average represents the concentration ± SEM of TGF-3 produced (ng/ml) 
at all time points in the media control supematants with or without in vitro infection with M. paratuberculosis. 
Y Number of animals in each group was five healthy cows, four subclinically infected cows and five clinically infected cows 
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Figure 1. Photomicrograph depicting the morphological appearance of peripheral blood 
mononuclear cells (PBMC) in all experimental groups following in vitro culture. (A) PBMC 
2 hours after isolation from the buffy-coat; (B) Unfractionated PBMC after 6 days in culture 
and before supematants replacement with fresh complete medium containing different 
cytokine treatments. The stellate morphology of cells in culture indicates the development of 
monocyte-derived macrophages. 
A: IFN-y 
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Figure 2. Cytokines production in the unfractionated peripheral blood cell culture of healthy 
and naturally M. paratuberculosis infected cows after LPS (E. coli Oil :B4) stimulation. (A) 
IFN y, (B) IL-10 and (C) TGF (3 production in cell culture supematants from non-infected 
healthy cows and cows with subclinical and clinical Johne's disease. PBMC culture media 
were replaced with complete medium at day 6. After 18 hours (day 7), cells in culture were 
stimulated with LPS (1 ng/ml). Culture supematants were collected at 8 hours, 3 days, and 6 
days after LPS stimulation and analyzed by ELISA. Data represent the concentration mean (± 
SEM) of each cytokine produced at all time points in the supematants of healthy (n=5), 
subclinically infected (n=4), or clinically infected cows (n=5) cell culture with or without in 
LPS stimulation. Different letters represent a statistical significance (P< 0.05). 
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Figure 3. Bactericidal activity of the unfractionated peripheral blood mononuclear cell 
culture recovered from healthy cows (n=5) or cows naturally infected with M. 
paratuberculosis (n=9). PBMC culture medium was replaced with complete medium at day 6 
and 18 hours later (day 7), cells in culture were infected with M. paratuberculosis at 10:1 
bacteria to adherent cell ratio. Data shown are the number of viable bacteria represented by 
the number of the colony forming unit (CPU) ± SEM recovered from cell culture lysates and 
supematants 6 days after in the vitro infection with M. paratuberculosis. Different letters 
represent statistically significant difference (P< 0.05). 
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Figure 4. The effect of exogenous cytokine stimulation on the bactericidal activity of the 
unfractionated peripheral blood mononuclear cell (PBMC) culture from healthy noninfected 
cows (n=5). After 6 days , PBMC culture supematants were replaced with fresh medium 
containing IFN y (100 ng/ml), IL-10 (100 ng/ml), TGF |3 (10 ng/ml), TGF (3 (10 ng/ml) + IL-
10 (3 (100 ng/ml) or left without stimulation (medium control). Eighteen hours later, cultures 
were infected with live M. paratuberculosis (10:1 bacteria to adherent cell ratio). Data shown 
are the number of viable bacteria represented by the number of the colony forming unit 
(CFU) ± SEM recovered from cell culture lysates and supematants 6 days after in the vitro 
infection with M. paratuberculosis. Different letters represent a statistical significance (P< 
0.05). 
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Figure 5. The overall effect of exogenous rTGF-(3 on endogenous IL-10 production in cell 
culture supernatant. PBMC culture medium were replaced at day 6 with complete medium 
containing exogenous rTGF-(3 (10 ng/ml) or left without stimulation (medium control). 
Culture supematants were collected 24 hours, 4 days, or 7 days after cytokine stimulation and 
analyzed by ELISA. Data represents the compression of all values regardless of time, LPS 
stimulation, or M. paratuberculosis infection and is presented as the concentration ± SEM. 
Different letters represent a statistical significance (P< 0.05). 
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Figure 6. The inhibitory effect of exogenous anti-inflammatory cytokines (IL-10 and TGF (3) 
on IFN y production. PBMC culture media were replaced at day 6 with fresh complete 
medium containing, IL-10 (100 ng/ml), TGF (3 (10 ng/ml), TGF (3 (10 ng/ml) + IL-10 (3 (100 
ng/ml) or left without stimulation (medium control). Cells in culture were infected on day 7 
with M. paratuberculosis (A) or left without infection (B) Culture supematants were 
collected 8 hours, 3 days, or 6 days after in vitro infection and analyzed by ELISA. Data 
represents the compression of all values regardless of time and presented, as the 
concentration ± SEM. Number of animals in each group was five healthy cows, four 
subclinically infected cows and five clinically infected cows. Different letters represent a 
statistical significance comparing the anti-inflammatory cytokine stimulation with medium 
control in all experimental groups (P< 0.05). 
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GENERAL CONCLUSIONS 
The susceptibility and resistance to M. paratuberculosis infection and disease progression 
represents a struggle between the bacteria and host immunity. The increased IFN-y 
production noted locally at the site of infection in the subclinical animals or as a result of in 
vitro infection with M. paratuberculosis represents an attempt by the host immune system to 
contain the infection. In this work, we proposed that cell-mediated immunity characterized 
by high IFN-y production noted in the subclinical stage of Johne's disease is downregulated 
by the induction of cytokines such as IL-10 and TGF-(3. The downregulation of cell-mediated 
immunity contributes to disease progression from the subclinical stage to clinical stage. 
To evaluate this hypothesis, we analyzed the gene expression of these cytokines locally at the 
site of infection as well as the draining lymph nodes of these sites. In chapter 2, tissue such 
from ileum, ileal-cecal junction, ileal-cecal lymph node and mesenteric lymph node were 
collected from healthy animals as well as from animals at subclinical and clinical stages of 
the disease. The gene expression for IFN-y, IL-10, and TGF-(3 were assessed by RT-PCR in 
all animal groups. We found an increased expression of TGF-(3 and IL-10 specific mRNA in 
the tissues of animals in the clinical stage of the disease and an upregulation of IFN-y gene 
expression in the subclinical stage of the disease. We then evaluated the effect of these 
cytokines on the ability of the monocyte-derived macrophages in unfractionated PBMC 
cultures to limit M. paratuberculosis survival. The profile of cytokine production in each 
group after in vitro infection was also evaluated. The results of these in vitro experiments 
revealed that animals at the subclinical stage of the disease had lower TGF-(3 production 
compared to healthy and clinically infected animals. After exposure to live M. 
paratuberculosis there was an upregulation of this cytokine only in the naturally infected 
animals and not in healthy animals. IL-10 production was also upregulated in infected 
animals after in vitro infection. Therefore, the upregulation of these cytokines that we noted 
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locally at the site of infection in the clinical animals might be a result of infection with M. 
paratuberculosis. 
In healthy animals, in vitro infection with M. paratuberculosis resulted in increased 
production of this cytokine at all time points tested. In contrast, IFN-y production by PBMC 
from clinically infected cows was high after 8 hours of M. paratuberculosis infection then 
decreased with time. This might be due to the increased production of IL-10 and TGF-(3 
reported in this group after the in vitro infection with live M. paratuberculosis. In the 
subclinical group, the IFN-y production remained constant after the in vitro infection with 
live M. paratuberculosis across the time points tested in this study. Therefore, cells obtained 
from all animals either healthy or naturally infected animals are capable of producing IFN-y 
after exposure to M. paratuberculosis but the dynamics of the IFN gamma response appear to 
be affected by the relative amount of the IL-10 or TGF-(3. 
In addition to the differences in the cytokine production noted in this study, cell phenotype 
was also noted to be different among groups. Before exposure of cells in culture to M. 
paratuberculosis, clinically infected animals had a higher percentage of B cells and MHC II 
B cells. The higher percentage of these cells may have affected the cytokine production in 
this study. Therefore, it might be informative to investigate the role of these cells in the 
pathogenesis of M. paratuberculosis infection and whether these cells are the source of the 
inhibitory cytokines, IL-10 and TGF-(3. 
Finally, in healthy animals, the correlation of the increased IFN-y production and the steady 
IL-10 and TGF-|3 production across time with M. paratuberculosis survival in the cell culture 
implies that such conditions favor increased bacterial killing by monocyte-derived 
macrophages in the unfractionated PBMC culture. In contrast, the culture conditions in both 
subclinical and clinically infected animals on average favor an increase IL-10 and TGF-(3 
production after M. paratuberculosis in vitro infection. Therefore, even with the presence of 
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IFN-y the bacterial survival in these cultures were high compared to healthy animals. This 
indicates that upregulation of IL-10 and TGF-(3 even with the presence of high IFN-y 
production results in less effective killing of the M. paratuberculosis. We also tested this 
hypothesis through the addition of IL-10 and TGF-(3 to the healthy animals cell culture and 
found that these cytokines inhibited the bactericidal activity as well as had a down regulatory 
effect on the IFN-y production in these cultures. Therefore, the results from these studies 
indicate that anti-inflammatory cytokines, IL-10 and TGF-(3 are induced and play a key role 
in the regulation of host immunity during M. paratuberculosis infection. 
I l l  
APPENDIX: CD5 EXPRESSION ON B CELLS 
Peripheral blood mononuclear cells (PBMC) from animals in the clinical stage of Johne's 
disease contain a high percentage of B cells (4). In this study we examined the level of CD5 
expression on B cells with the understanding that this may be indicative of B1 cells. Flow 
cytometric analysis was performed on PBMC culture in the presence or absence of M. 
paratuberculosis and the key regulatory cytokines such as IFN-y, IL-10, and TGF-(3. We 
reported the presence of two populations of CD5+ B cells, one population CD5bnght and the 
other population CD5d,m (Figure 1). We also found a correlation between the percentage of 
CD5bnght B cells and the disease stage of M. paratuberculosis infection (Figure 2). A previous 
study reported an increase in the number of B cells in clinically infected animals (4). These B 
cells did not proliferate in response to antigen-specific stimulation with M. paratuberculosis 
whole cell sonicate (WCS) but proliferated after the addition of ConA to the culture medium. 
In contrast, B cells obtained from subclinically infected cows demonstrated a normal antigen-
specific proliferative response to M. paratuberculosis WCS (4). In present study, we 
demonstrated that 78% of the B cells in the clinically infected animals were CD5bnght. 
However, the percentage of CD5bnght B cells in PBMC obtained from animals with subclinical 
Johne's disease did not exceed 47% of the total B cells and an even lower percentage noted 
for PBMC from healthy animals (34%). Culturing PBMC from healthy, subclinical, or 
clinical Johne's cows resulted in downregulation of CD5 expression on B cells in all groups 
(Figure 3A). Culturing PBMC with live M. paratuberculosis (Figure 3B) increased the 
percentage of the CD5bnght B cells in cultures from subclinically infected cows but not in 
cultures from healthy cows or clinically infected cows. Activation of cells in culture with 
cytokines such as IFN y, IL-10, or TGF p slightly increased the percentage of the CD5br'Eht B 
cells in cultures compared to cells cultured in medium alone (Figure 3A). It should be noted 
that these changes were only observed in cells recovered from subclinically infected animals 
and not those from healthy or clinically infected animals. 
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Bovine leukemia virus (BLV) infection in cows is known to be associated with an increased 
population of CD5+ B cells (2). In our study, the increased percentage of CD5bnght B cells 
after cytokine treatment or after in vitro infection with live M. paratuberculosis was not 
affected by the presence or absence of BLV infection. Cells from both BLV positive and 
BLV negative cows with subclinical disease had a significantly increased percentage of 
CD5bnght B cells (Table 1). None of the clinically infected cows tested negative for BLV; 
therefore, it is difficult to speculate if the high percentage of CD5+ B cells found in the 
clinical animals is a result of M. paratuberculosis, BLV, or both infections. Taking that into 
consideration, we hypothesize that there might be a relation between the presence of CD5bnght 
B cells and the progression of Johne's disease. Whether this correlation relates to a cause or 
effect relative to clinical disease is unknown, but it is tempting to speculate that a ubiquitous 
agent such as BLV may hasten the progression of disease in M. paratuberculosis infection 
from subclinical infection to clinical disease. 
Materials and Methods 
Animals. PBMC were collected from 9 healthy cows, 17 cows naturally infected with M. 
paratuberculosis but asymptomatic (i.e., subclinical), and 9 cows with clinical Johne's 
disease. The Holstein dairy cows used in this experiment were monitored by frequent testing 
for the fecal shedding of M. paratuberculosis using standard culture methods as previously 
described (3). By definition, clinical animals were shedding more than 100 colony forming 
units (CPU) per gram of feces and presented with weight loss and intermittent diarrhea. 
Subclinically infected cows were shedding less than 10 CFU/g of feces and were otherwise 
asymptomatic. All animals in the experiment were approved by the IACUC.and housed in 
American Association for Accreditation of Laboratory Animal Care-accredited facilities 
(National Animal Disease Center, Ames, Iowa). 
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Blood collection, culturing conditions and sample collection. Blood was collected from 
the jugular vein into 2X acid-citrate-dextrose (ACD) (1:10). Peripheral blood mononuclear 
cells (PBMC) were isolated from the buffy-coat fractions of the peripheral blood as 
previously described (1). PBMC were re-suspended in RPMI-1640 (Gibco, Grand Island, 
NY) containing 10% PCS (Atlanta Biologies, Atlanta, GA.), 100 units/ml penicillin G 
sodium (Gibco) 100 jug/ml streptomycin sulfate (Gibco), 0.25 pig/ml amphotericin B (Gibco), 
and 2 mM L-glutamine (Gibco). Cells were cultured at 2 x 106/ ml in 24-well flat-bottomed 
plates (Nunc, Life Technologies) at 39°C in 5% C02 in a humidified atmosphere. Cells in 
culture were stimulated with 100 ng/ml human IL-10 (200-10, Peprotech, Rocky Hill, N.J.), 
100 ng/ml bovine IFN-y (generously donated by Novartis Animal Health, Basel, 
Switzerland), 10 ng/ml human TGF (3 (100-21R, Peprotech), 100 ng/ml IL-10 plus 10 ng/ml 
TGF-(3 or left without cytokine stimulation. PBMC were in vitro infected with live M. 
paratuberculosis, strain 19698 (NADC, Ames, IA) at a ratio of 10 bacteria per cell. Cells 
were collected for flow cytometric analysis at 8, 24, and 72 hours after cytokine treatments 
and in vitro infection with M. paratuberculosis. 
Bacteria. M. paratuberculosis strain 19698 (NADC) was grown in Middle-brook 7H9 broth 
(pH 6.0) supplemented with oleic acid albumin dextrose complex (OADC, Becton Dickinson 
Microbiology). The bacteria were harvested, washed three times with phosphate buffer saline 
(PBS), resuspended in PBS to a final concentration of 10*/ml as determined by the 
absorbance at 540 nm. Bacterial stocks were then frozen in PBS at -80°C until used in the 
experiments. Prior to in vitro infection, frozen bacterial stocks were thawed and clumps were 
dispersed by brief sonication at 25 W for 40 sec with a Tekmar sonic disturber. The frozen 
bacterial stocks were monitored for viable count by culturing on HEYM. Viable counts in 
stocks were reduced after thawing and sonication to approximately around 108CFU/ml. 
Assessment of expression of CD5+ cell surface marker on B cells. For analysis of the 
expression of CD5 on B cells, two-color flow cytometry protocol was used. Briefly, 100 |il 
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of cell cultures at 2 x 106 cells/ml were incubated for 20 min at RT with 50 (il of a 
monoclonal antibody specific for a B cell marker (BAQ155A 7p.g/ml, VMRD) and 50 p,l of a 
monoclonal antibody specific for CD5 (B29A 7 ng/ml, VMRD). Cell surface markers were 
then visualized by incubating cells for 20 min with 50 pi of phycoerythrin-conjugated goat 
anti-mouse IgG2a (Southern Biotechnology Associates, Inc., Birmingham, AL) diluted at 
1:500 (vol/vol) to detect cells labeled with anti-CD5 marker and 50 |iil of PerCP conjugated 
rat anti-mouse IgGl (Beeton Dickinson Immunocytochemistry Systems, San Jose, CA) 
diluted at 1:25 (vol/vol) to detect cells labeled with anti-B cell monoclonal antibody. Cells 
were then washed and resuspended in FACS buffer (PBS, 1% PCS, 0.01% sodium azide) 
containing DAPI stain at 1:1000 (10 mg/ml) (Sigma, St. Louis, MO) in order to eliminate 
dead cells from the analysis. Cells were then washed and resuspended in FACS buffer and 
analyzed the same day by flow cytometry. Data from 5000 events that were DAPI negative 
(i.e., live cells) per sample were acquired (Cell quest software; BD Biosciences, San Jose, 
CA) using a FACSCAN flow cytometer (BD, LSR). Data were analyzed using Flowjo 
software (Tree Star Inc, San Carlos, CA). 
Statistical analysis. Results were compared by using ANOVA, and significant differences 
between means were tested by Fisher protected least significant difference test using the 
Statview software package (Graphpad software, San Diego, C. A.). For all tests and 
comparisons only P value less than 0.05 were considered significant. 
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Figure 1. Flow cytometric analysis of CD5+ B cells in PBMC cultures obtained from a 
representative healthy cow after 24 hours in vitro culture (A), subclinically infected cow (B), 
clinically infected cow (C). The B cells were examined for CD5 expression using two-color 
flow cytometry. Cells were reacted with a monoclonal antibody (BAQ155A) that defines 
bovine B cells and monoclonal antibody (B29A), which identifies CD5. Three populations of 
B cells were noted: CD5" B cells (gate 1), CD5dim B cells (gate 2) and CD5bnght B cells (gate 
3) that had the same level of CD5 expression as observed for the distinct non B cell CD5 + 
population. 
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Figure 2. Peripheral blood mononuclear cells from healthy (n=9), subclinical (n=17) or 
clinical infected cows (n=9) were isolated, stained and analyzed by flow cytometry. Data 
represent the percentage of CD5bnght B cells from the total B cell population (± S EM). 
Different letters represent a statistical difference (P< 0.05). 
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Figure 3. The percentage of CD5bnght B cells from the total B cell population in PBMC 
cultures obtained from healthy, subclinical or clinical infected cows. Cells were cultured for 
in medium alone (no cytokine stimulation), IFN y (100 ng/ml), IL-10 (100 ng/ml), TGF 
(3 (10 ng/ml), or the combination of TGF (3 (10 ng/ml) + IL-10 (100 ng/ml) (A). In addition to 
these cytokines, cells in culture were also infected with live M. paratuberculosis at 10:1 
bacteria to cell ratio (B). Cells were collected for flow analysis at 8, 24 and 72 hours after 
cytokine treatments or in vitro infection. Data represent the average percentage of CD5bnght B 
cells at all time points ± SEM. 
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Table 1. Percentages of CD5bnght expressed on B cells obtained from subclinical^ infected 
cows (n=17) that were seropositive (n=7) for bovine leukemia virus (BLV) or were found to 
be seronegative (n=10) for BLV infection. 
BLV status Medium control In vitro infected with M. paratuberculosis 
Negative 31.0" ±2.02 46.4" ± 3.06 
Positive 38.la ± 0.71 52.0b± 1.72 
Cells in culture were infected with M. paratuberculosis at 10:1 bacteria to cell ratio or were 
not infected. Data represents the average for all the time points tested in this study (8 hours, 3 
days and 6 days). 
